var title_f5_18_5408="Gram stain sputum 12B answer";
var content_f5_18_5408=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aspergillus fumigatus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Swartz-Lamkin's wet mount of the same sputum (x1000) shows uniform septate hyphae which branch at 45&ordm;. Aspergillus fumigatus grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_18_5408=[""].join("\n");
var outline_f5_18_5408=null;
var title_f5_18_5409="Nonfunctioning thyroid nodule";
var content_f5_18_5409=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F68835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F68835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nonfunctioning thyroid nodule: Appearance on thyroid scintigraphy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    123-I thyroid scan demonstrating typical appearance of a large, 3.5 cm hypofunctioning (\"cold\") nodule in the left upper lobe of the thyroid. The position of the nodule is outlined in white.",
"    <div class=\"footnotes\">",
"     SSN: suprasternal notch.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas Ross, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_18_5409=[""].join("\n");
var outline_f5_18_5409=null;
var title_f5_18_5410="Duodenal amyloid Congo red";
var content_f5_18_5410=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amyloidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 242px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic biopsy of nodular appearing duodenal mucosa stained with Congo red. Note the positive staining of the lamina propria and blood vessels (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Camilleri, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_18_5410=[""].join("\n");
var outline_f5_18_5410=null;
var title_f5_18_5411="Pudendal block";
var content_f5_18_5411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Pudendal block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 593px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_18_5411=[""].join("\n");
var outline_f5_18_5411=null;
var title_f5_18_5412="Potassium acetate: Pediatric drug information";
var content_f5_18_5412=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium acetate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?35/12/36036?source=see_link\">",
"    see \"Potassium acetate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/50/40739?source=see_link\">",
"    see \"Potassium acetate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1031972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. doses should be incorporated into the patient's maintenance I.V. fluids; intermittent I.V. potassium administration should be reserved for severe depletion situations; continuous ECG monitoring should be used for intermittent doses &gt;0.5 mEq/kg/",
"     <b>",
"      hour",
"     </b>",
"     .",
"     <b>",
"      Note:",
"     </b>",
"     Doses listed as mEq of",
"     <b>",
"      potassium",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Normal daily requirement: I.V.: 2-6 mEq/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of hypokalemia: Intermittent I.V. infusion (must be diluted prior to administration): 0.5-1 mEq/kg/dose, infuse at 0.3-0.5 mEq/kg/",
"     <b>",
"      hour",
"     </b>",
"     (maximum dose/rate: 1 mEq/kg/",
"     <b>",
"      hour",
"     </b>",
"     ); then repeated as needed based on frequently obtained lab values; severe depletion or ongoing losses may require &gt;200% of normal daily limit needs",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1031993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/12/36036?source=see_link\">",
"      see \"Potassium acetate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. doses should be incorporated into the patient's maintenance I.V. fluids; intermittent I.V. potassium administration should be reserved for severe depletion situations; continuous ECG monitoring should be used for intermittent doses &gt;0.5 mEq/kg/",
"     <b>",
"      hour",
"     </b>",
"     .",
"     <b>",
"      Note:",
"     </b>",
"     Doses listed as mEq of",
"     <b>",
"      potassium",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normal daily requirement: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 2-6 mEq/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2-3 mEq/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 40-80 mEq/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of hypokalemia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermittent I.V. infusion (must be diluted prior to administration): 0.5-1 mEq/kg/dose (maximum dose: 40 mEq), infuse at 0.3-0.5 mEq/kg/",
"     <b>",
"      hour",
"     </b>",
"     (maximum dose/rate: 1 mEq/kg/",
"     <b>",
"      hour",
"     </b>",
"     ); then repeated as needed based on frequently obtained lab values; severe depletion or ongoing losses may require &gt;200% of normal daily limit needs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermittent I.V. infusion: 5-10 mEq/hour (continuous cardiac monitor recommended for rates &gt;5 mEq/hour), not to exceed 40 mEq/hour; usual adult maximum per 24 hours: 400 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Potassium dosage/rate of infusion guidelines:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Serum potassium &ge;2.5 mEq/L (and &lt;desired): 10 mEq with additional doses if needed; maximum infusion rate: 10 mEq/hour; maximum 24-hour dose: 200 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Serum potassium &lt;2.5 mEq/L: Up to 40 mEq with additional doses based upon frequent lab monitoring; maximum infusion rate: 40 mEq/hour; maximum 24-hour dose: 400 mEq; deficits at a plasma level of 2 mEq/L may be as high as 400-800 mEq of potassium",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 2 mEq/mL (20 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 2 mEq/mL (20 mL, 100 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate, preservative free]: 4 mEq/mL (50 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1031998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Potassium must be diluted prior to parenteral administration; maximum recommended concentration (peripheral line): 80-100 mEq/L; maximum recommended concentration (central line): 150 mEq/L or 15 mEq/100 mL; in severely fluid-restricted patients (with central lines): 200 mEq/L or 20 mEq/100 mL has been used; maximum rate of infusion",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F1031988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Ciprofloxacin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility when admixed: Compatible:",
"     </b>",
"     Metoclopramide",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F4603487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; do not freeze",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1031973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and prevention of hypokalemia when it is necessary to avoid chloride or acid/base status requires an additional source of bicarbonate",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F211553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Consider special storage requirements for intravenous potassium salts; I.V. potassium salts have been administered IVP in error, leading to fatal outcomes.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F211550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, EEG abnormalities, heart block, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, listlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paralysis, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Local tissue necrosis with extravasation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1031975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the potassium supplement; severe renal impairment, untreated Addison's disease, heat cramps, hyperkalemia, severe tissue trauma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4603486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiac disease, patients receiving potassium-sparing drugs; patients should be on a cardiac monitor during intermittent infusions for doses &gt;0.5 mEq/kg/hour or 5 mEq/hour (adults); solution for injection contains aluminum; use caution with impaired renal function and in premature infants",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1031976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potassium acetate should be administered only in patients with adequate urine flow; must be diluted before I.V. use and infused slowly",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F211519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13889738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Potassium requirements are the same in pregnant and nonpregnant women. Adverse events have not been observed following use of potassium supplements in healthy women with normal pregnancies. Use caution in pregnant women with other medical conditions (eg, pre-eclampsia; may be more likely to develop hyperkalemia) (IOM,  2004).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4603488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, glucose, chloride, pH, urine output (if indicated), cardiac monitor [if intermittent I.V. infusion or potassium I.V. infusion rates &gt;0.5 mEq/kg/hour or 5 mEq/hour (adults)]",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1031989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potassium is the major cation of intracellular fluid and is essential for the conduction of nerve impulses in heart, brain, and skeletal muscle; contraction of cardiac, skeletal, and smooth muscles; maintenance of normal renal function, acid-base balance, carbohydrate metabolism, and gastric secretion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1031990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Enters cells via active transport from extracellular fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily urine; skin and feces (small amounts); most intestinal potassium reabsorbed",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1032002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1 mEq of acetate is equivalent to the alkalinizing effect of 1 mEq of bicarbonate. Hypokalemia is highly arrhythmogenic, particularly in the setting of ischemia or digitalis toxicity. ECG evidence of hypokalemia includes flattening of the T wave. As the T wave shrinks, U waves may appear. There is no prolongation of the QT interval. Hyperkalemia may present as tall peaked symmetrical T waves. S-T elevation may present in severe hyperkalemia. QRS complex progressively widens with eventual apparent sine waves on the ECG. Hyperkalemia will also induce cardiac slowing and AV conduction abnormalities.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hamill RJ, Robinson LM, Wexler HR, et al, &ldquo;Efficacy and Safety of Potassium Infusion Therapy in Hypokalemic Critically Ill Patients,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1991, 19(5):694-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/18/5412/abstract-text/2026032/pubmed\" id=\"2026032\" target=\"_blank\">",
"        2026032",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khilnani P, &ldquo;Electrolyte Abnormalities in Critically Ill Children,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1992, 20(2):241-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/18/5412/abstract-text/1737458/pubmed\" id=\"1737458\" target=\"_blank\">",
"        1737458",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13033 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_18_5412=[""].join("\n");
var outline_f5_18_5412=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1031972\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444784\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1031993\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211523\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211510\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1031998\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1031988\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4603487\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1031973\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211553\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211550\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1031975\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4603486\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1031976\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299911\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211519\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211520\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13889738\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4603488\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1031989\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1031990\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032002\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13033\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13033|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/12/36036?source=related_link\">",
"      Potassium acetate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/50/40739?source=related_link\">",
"      Potassium acetate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_18_5413="Acne mixed type";
var content_f5_18_5413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inflammatory and noninflammatory acne",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The face of this teenager shows open and closed comedones, papules, and pustules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_18_5413=[""].join("\n");
var outline_f5_18_5413=null;
var title_f5_18_5414="3D echo mitral valve";
var content_f5_18_5414=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Real-time three-dimensional (3D) echocardiogram showing volumetric imaging and analysis of the mitral valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     (Top)",
"    </strong>",
"    Baseline image before mitral balloon valvuloplasty (A) shows a restricted mitral valve opening with bicommissural fusion. Post-valvuloplasty, splitting of the medial commissure and posterior leaflet tear can be seen (B).",
"    <br>",
"     <strong>",
"      (Bottom)",
"     </strong>",
"     Example of 3D reconstruction of the mitral annulus (C) and leaflets (D) obtained in a patient with dilated cardiomyopathy, demonstrating the saddle shape of the annulus and increased leaflet tenting volume.",
"     <div class=\"footnotes\">",
"      RV: right ventricle; IVS: interventricular septum.",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Victor Mor-Avi, PhD and Roberto M Lang, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_18_5414=[""].join("\n");
var outline_f5_18_5414=null;
var title_f5_18_5415="ERCP after Billroth II reconstruction";
var content_f5_18_5415=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ERCP after Billroth II reconstruction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/18/5415/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/18/5415/contributors\">",
"     Guido Costamagna, MD, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/18/5415/contributors\">",
"     Silvano Loperfido, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/18/5415/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/18/5415/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/18/5415/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/18/5415/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/18/5415/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Billroth II operation entails partial gastrectomy with end-to-side gastrojejunostomy (",
"    <a class=\"graphic graphic_figure graphicRef60887 \" href=\"UTD.htm?27/46/28385\">",
"     figure 1",
"    </a>",
"    ). It is usually performed to treat complications of peptic ulcer disease (such as perforation, bleeding, penetration, and duodenal stricture) or gastric carcinoma localized at the antrum. The operation was named after Theodor Billroth, who first performed it in January 1885. Although significantly less often performed in recent years, thanks to revolutionary changes in the conservative management of peptic ulcer disease (H2 blockers and proton pump inhibitors), the Billroth II operation is still the most widely used reconstruction after distal stomach resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33688?source=see_link&amp;anchor=H9#H9\">",
"     \"Role of surgery in the management of peptic ulcer disease\", section on 'Truncal vagotomy with antrectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the surgically altered anatomy, diagnostic and therapeutic endoscopic retrograde cholangiopancreatography (ERCP) is more difficult in patients with previous Billroth II gastrectomy compared with patients with native anatomy. The papillary area in the second part of the duodenum can only be reached through the afferent loop. As a result, the papilla of Vater appears upside-down compared with its orientation during standard ERCP (",
"    <a class=\"graphic graphic_figure graphicRef60887 \" href=\"UTD.htm?27/46/28385\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The endoscopist performing ERCP in a Billroth II patient has to consider and overcome the following issues:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Choosing the appropriate endoscope",
"     </li>",
"     <li>",
"      Entering the afferent loop",
"     </li>",
"     <li>",
"      Reaching the duodenal stump",
"     </li>",
"     <li>",
"      Cannulating the papilla from a reverse position",
"     </li>",
"     <li>",
"      Performing an endoscopic sphincterotomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These considerations were addressed by a number of specialists shortly after the introduction of ERCP in 1968 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/1\">",
"     1",
"    </a>",
"    ] and endoscopic sphincterotomy in 1973 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/2\">",
"     2",
"    </a>",
"    ]. However, interest in these issues continues to the present and will be discussed here [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/3-9\">",
"     3-9",
"    </a>",
"    ]. ERCP in patients with Roux-en-Y anatomy and other issues related to ERCP are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37831?source=see_link\">",
"     \"ERCP in patients with Roux-en-Y anatomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=see_link\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23959?source=see_link\">",
"     \"Post-ERCP septic complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=see_link\">",
"     \"Post-ERCP pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26216?source=see_link\">",
"     \"Post-ERCP bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Billroth II anastomosis is created after the proximal stomach is transected at the antrum and the duodenum is divided distal to the pyloric ring. One of two techniques is then used to reconstruct the anatomy (",
"    <a class=\"graphic graphic_figure graphicRef68578 \" href=\"UTD.htm?18/20/18752\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Hofmeister technique, in which the half of the gastric resection line closest to the lesser curvature is sutured, and the lower half (ie, closest to the greater curvature) is anastomosed to the proximal jejunum",
"     </li>",
"     <li>",
"      The Polya technique, in which the gastrojejunal anastomosis includes the entire length of the gastric resection line",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both techniques, the afferent and efferent jejunal limbs can be separated by a wide or a narrow distance, depending upon the size of the stoma. The position of the efferent and afferent limbs relative to one another is variable (",
"    <a class=\"graphic graphic_figure graphicRef68578 \" href=\"UTD.htm?18/20/18752\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Apart from Billroth II anastomosis, there are other conditions with surgically altered anatomy that make the performance of ERCP challenging and can increase the risk of complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37831?source=see_link\">",
"     \"ERCP in patients with Roux-en-Y anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These conditions include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total gastrectomy (",
"      <a class=\"graphic graphic_figure graphicRef61753 \" href=\"UTD.htm?2/13/2261\">",
"       figure 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Roux-en-Y gastrojejunostomy (",
"      <a class=\"graphic graphic_figure graphicRef79256 \" href=\"UTD.htm?32/35/33329\">",
"       figure 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Roux-en-Y hepaticojejunostomy (",
"      <a class=\"graphic graphic_figure graphicRef67421 \" href=\"UTD.htm?29/21/30036\">",
"       figure 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Standard pancreaticoduodenectomy (Whipple operation) (",
"      <a class=\"graphic graphic_figure graphicRef82519 \" href=\"UTD.htm?16/57/17303\">",
"       figure 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pylorus preserving pancreaticoduodenectomy (",
"      <a class=\"graphic graphic_figure graphicRef60689 \" href=\"UTD.htm?5/43/5810\">",
"       figure 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other forms of bariatric surgery (eg, biliopancreatic diversion) (",
"      <a class=\"graphic graphic_figure graphicRef67432 \" href=\"UTD.htm?18/53/19284\">",
"       figure 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef70168 \" href=\"UTD.htm?7/18/7457\">",
"       figure 9",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CHOOSING THE APPROPRIATE ENDOSCOPE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17696848\">",
"    <span class=\"h2\">",
"     Forward-viewing versus side-viewing endoscopes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice between a forward-viewing and side-viewing endoscope is a matter of continued debate. Some authorities advocate the routine use of forward-viewing endoscopes (eg, gastroscopes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/6,9\">",
"     6,9",
"    </a>",
"    ] or even pediatric colonoscopes to manage long afferent loops [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/10\">",
"     10",
"    </a>",
"    ]) because they are easier to use and can facilitate recognition of the afferent loop. The major drawback of forward-viewing endoscopes is the lack of an elevator at the operative channel once the papillary area has been reached.",
"   </p>",
"   <p>",
"    This limitation underlies the recommendation of other authorities who routinely use side-viewing duodenoscopes, believing that, with experience, the ease of identification of the afferent loop and papilla is comparable to the forward viewing endoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/11\">",
"     11",
"    </a>",
"    ]. This issue was addressed in a prospective randomized trial that included 45 patients with a Billroth II gastrectomy who were randomized to ERCP with biliary sphincterotomy using either a forward- or side-viewing endoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/6\">",
"     6",
"    </a>",
"    ]. Cannulation was more often successful with the forward-viewing instrument (87 versus 68 percent). In patients in whom cannulation was successful, the rate of successful sphincterotomy was comparable between the groups (83 versus 80 percent, respectively). Another possible advantage of the forward-viewing endoscope was a lower rate of complications; jejunal perforation occurred in four patients with the side-viewing endoscope compared with none with the forward-viewing endoscope.",
"   </p>",
"   <p>",
"    However, a major limitation of this study was the type of side-viewing endoscope used (the TJF V10, Olympus Co, Tokyo, Japan), which has a long and potentially harmful distal end. The only jejunal perforation reported in another series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/7\">",
"     7",
"    </a>",
"    ] occurred with the same type of scope, which was very soon replaced by the TJF 100 (Olympus), a scope with a smooth, regular distal end that maintains a 4.2 mm wide operative channel. Thus, while the risk of jejunal perforation occurring during progression within the afferent loop is not entirely absent with the currently available therapeutic duodenoscopes, it should be significantly lower than in the above series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, all series of ERCP in Billroth II patients have described serious perforations; one series described a perforation rate of 6 percent with 82 percent requiring laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our experience (over a 22-year period), only 11 perforations were recorded during 855 ERCPs (1.3 percent) in 537 patients with a Billroth II gastric resection. All the procedures were started with an operative side-viewing endoscope. The duodenal stump was intubated and the papilla of Vater correctly identified in 477 patients (89 percent) and in 98 percent of cases at the first attempt. A forward-viewing endoscope was used only as a second choice after a failed approach with a side-viewing endoscope. Failure in duodenal intubation was due to jejunal perforation in 11 patients and to angled",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    long jejunal loops in 49 patients. When the duodenal stump had been correctly intubated, biliary or pancreatic duct cannulation was successful in 93 percent of cases. A purely diagnostic ERCP was performed in 76 patients (17 percent). Overall, ERCP-related morbidity and mortality were 3.4 and 0.1 percent, respectively (one patient died because of complications related to the jejunal perforation) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar experience has been described in several other series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/3,7,8,14\">",
"     3,7,8,14",
"    </a>",
"    ], with only a few exceptions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. In contrast, preferential use of a forward-viewing endoscope has been associated with a lower success rate. In a series of 56 patients, for example, a forward-viewing endoscope was associated with successful afferent loop entrance in only 77 percent, cannulation in 81 percent of those with successful afferent loop entrance, and an overall success rate of Billroth II ERCP of only 63 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/9\">",
"     9",
"    </a>",
"    ]. Ten of the failed cases were retried by side-viewing duodenoscope; five were successfully completed.",
"   </p>",
"   <p>",
"    At present, most specialists recommend the routine use of a side-viewing duodenoscope for ERCP in Billroth II patients. Forward-viewing endoscopes should be reserved for use after a failed attempt with the duodenoscope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17696840\">",
"    <span class=\"h2\">",
"     Other endoscopes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal instrument for ERCP in patients with surgically altered anatomy would blend the best features of both the forward-viewing endoscope and the side-viewing duodenoscope, including an elevator and an angle of view that is a compromise between the two instruments [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/15\">",
"     15",
"    </a>",
"    ]. Some reports from Japan appear to support the use of an oblique-viewing endoscope in patients with prior Billroth II gastrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/16\">",
"     16",
"    </a>",
"    ] or Roux-en-Y reconstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/17\">",
"     17",
"    </a>",
"    ]. However, further studies are needed to confirm these results. In addition, oblique-viewing endoscopes are not commercially available in western countries.",
"   </p>",
"   <p>",
"    The utility of a multibending, forward-viewing endoscope for selective cannulation during ERCP in patients with a Billroth II gastrectomy has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intubation of the duodenal stump using conventional forward- or side-viewing endoscopes may occasionally be impossible in patients with a relatively long afferent loop. An increasing number of case reports have described success using balloon-assisted enteroscopy (both double and single balloon endoscopy) in patients with Billroth II gastrectomy or Roux-en-Y anastomosis, but experience is still limited, and the necessary equipment (including long ERCP catheters) is not widely available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24649?source=see_link\">",
"     \"Overview of deep small bowel enteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17696948\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Performing an ERCP in patients with Billroth II anatomy requires that the afferent loop be identified and entered, that the duodenal stump be reached, and that the papilla be cannulated. In many cases, an endoscopic sphincterotomy is also performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Entering the afferent loop",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first problem to be solved when attempting ERCP in patients with Billroth II anatomy is identification of the afferent loop at the site of the gastrojejunostomy. The loop adjacent to the lesser curve is usually examined first since it is more likely to lead to the afferent loop. However, fluoroscopy is often more accurate in showing the direction toward the right hypochondrium.",
"   </p>",
"   <p>",
"    Entering the afferent loop is sometimes extremely difficult, especially when the lesser curve remnant is short and the anastomosed loop is \"hung up\". When using a side-viewing duodenoscope, the endoscopic procedure is usually started with the patient lying in the left lateral position. However, turning the patient to the supine or prone position may improve the axis and facilitate introduction of the scope into the stoma.",
"   </p>",
"   <p>",
"    If these maneuvers are unsuccessful, the stoma can be cannulated with a J-tipped Teflon-coated or stiff hydromer-coated guidewire that is subsequently made rigid using a 10 French biliary bougie-type dilator (Soehendra dilator, Wilson Cook Med, Inc, Winston Salem, NC). The scope can then be pushed over the bougie, which acts as a straightener. Similar techniques using a biopsy forceps [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/8\">",
"     8",
"    </a>",
"    ] or a polypectomy snare [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/9\">",
"     9",
"    </a>",
"    ] have also been described but are probably less effective and riskier. All these maneuvers are safer and more effective if performed with close radiologic monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reaching the duodenal stump",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technique of scope progression into the afferent loop closely resembles techniques used during colonoscopy. One or more straightening maneuvers are often necessary to manage long loops and to obtain a better working position when the tip of the scope faces the papillary area. Straightening maneuvers may occasionally employ a clockwise or counterclockwise rotation of 360 degrees that requires detaching the scope insertion from the video-processor to avoid a complete loop on the scope light-cable. Having the scope in the \"short\" position (straightened scope) allows precise maneuvers during attempts at cannulation.",
"   </p>",
"   <p>",
"    Moving the patient to the supine position often facilitates progression of the scope into the afferent loop because it allows more precise radiologic orientation. In addition, infusion of contrast into the jejunal loop by air insufflation or by contrast injection through the operative channel helps to define the bowel anatomy when acute angles hinder progression of the scope. The supine position also permits hand compression over the abdomen to reduce loops formed by the endoscope.",
"   </p>",
"   <p>",
"    Other authors suggest that the use of a cap-fitted, frontal-viewing endoscope could be a major advantage for afferent loop identification, intubation of the duodenal stump, and duct cannulation. The cap could provide a fixed distance between the jejunal wall and the tip of the endoscope, and thus improve the identification of sharp angulations. It also displaces the jejunal folds during the progression of the endoscope and reduces the need for air inflation and, consequently, loop formation. Furthermore, the cap could help biliary cannulation by fixing the tip of the endoscope in the appropriate position in front of the papilla [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cannulating the papilla from the reverse position",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the side-viewing duodenoscope, the papilla of Vater appears in a completely reverse position to its orientation during standard ERCP. Cannulation and injection of the pancreatic duct is usually not a major problem because the duct joins the duodenum at a favorable angle. However, bile duct cannulation is more demanding.",
"   </p>",
"   <p>",
"    Since the majority of cannulas tend to assume an upward curve, most authorities use a straight catheter to improve the axis toward the biliary direction (ie, 5 to 6 o'clock, which is the opposite of the routine position in patients with unaltered gastroduodenal anatomy). The biliary orientation of the catheter may be further increased by slightly pulling back the duodenoscope, bending the tip of the duodenoscope toward the duodenal wall, and pushing the catheter while keeping its tip in contact with the papillary orifice.",
"   </p>",
"   <p>",
"    It is sometimes useful to modify the tip of the catheter by bending the distal part into a sigmoid shape. Every manipulation of the catheter should be carefully monitored with fluoroscopy, which is often much more helpful than the endoscopic view. When the papilla is close to or within a duodenal \"cul de sac\", cannulation may be more demanding or sometimes impossible. Other anatomic abnormalities, such as parapapillary diverticula, may hinder cannulation as in the patient with native anatomy.",
"   </p>",
"   <p>",
"    As discussed above, a side-viewing duodenoscope with an elevator is a major advantage in this phase of the procedure. Compared with the forward-viewing scope, it permits much more precise manipulation of catheters.",
"   </p>",
"   <p>",
"    Deep cannulation of the bile duct is as important in patients with Billroth II anatomy as in those with native anatomy. Catheters accepting a 0.035 inch guide-wire (which can be left in place to guide further therapeutic maneuvers) should be encouraged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Endoscopic sphincterotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many techniques have been proposed for performing endoscopic sphincterotomy in patients with Billroth II anatomy. As mentioned above, the main technical problem is due to the reverse position of the papilla in the endoscopic field. Because of this, the wire of the sphincterotome should cut, ideally, in a 6 o'clock direction. Sphincterotomes designed to facilitate this orientation have been available for more than 20 years. One design, for example, involved a sigmoid-shaped sphincterotome that had a long distal tip (long \"nose\"), which was supposed to rotate once deeply inserted into the common bile duct [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/2\">",
"     2",
"    </a>",
"    ]. Several other groups have designed similar catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/4,10,21,22\">",
"     4,10,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All of these devices require deep cannulation of the common bile duct, which guarantees the sphincterotomy to be as safe as possible, provided it is correctly directed. However, most of these sphincterotomes have proved difficult to orient properly during routine use. As a result, some authorities use a needle knife to carry out a complete \"free hand\" cutting of the papillary roof [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/23\">",
"     23",
"    </a>",
"    ]. This method, although simple and effective in expert hands, does not meet any of the safety criteria accepted for the non-gastrectomized patient, particularly since it does not require deep cannulation of the common bile duct. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/10/25767?source=see_link\">",
"     \"Precut (access) papillotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The \"free hand\" technique was later replaced by the \"over the stent\" needle knife technique [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/24\">",
"     24",
"    </a>",
"    ]. This modification offers the advantage of a controlled cutting direction thanks to a previously inserted biliary stent, and is now widely used in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/8\">",
"     8",
"    </a>",
"    ]. Nevertheless, both techniques probably carry a higher risk of retroperitoneal perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Balloon dilatation of the papilla (\"sphincteroplasty\" or \"sphincteroclasy\") has also been suggested as an alternative technique to avoid technical problems of endoscopic sphincterotomy in Billroth II patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/5,26-28\">",
"     5,26-28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37175?source=see_link\">",
"     \"Endoscopic balloon dilatation for removal of bile duct stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapeutic maneuvers that can be performed in the patient with unaltered gastroduodenal anatomy, such as stone extraction, drain insertion, and stent placement, are also feasible in patients with Billroth II anatomy once access to the bile duct has been obtained via endoscopic sphincterotomy or sphincteroplasty. All of these procedures should be performed only by highly experienced endoscopists [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pancreatic sphincterotomy at the major papilla as well as minor papilla sphincterotomy have also been performed safely in the setting of various pancreatic diseases (mainly chronic pancreatitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5415/abstract/30,31\">",
"     30,31",
"    </a>",
"    ] in patients with Billroth II anatomy by adapting the technique to the modified endoscopic view and following the same principles as for biliary sphincterotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17696866\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Billroth II operation entails partial gastrectomy with end-to-side gastrojejunostomy (",
"      <a class=\"graphic graphic_figure graphicRef60887 \" href=\"UTD.htm?27/46/28385\">",
"       figure 1",
"      </a>",
"      ). It is usually performed to treat complications of peptic ulcer disease (such as perforation, bleeding, penetration, and duodenal stricture) or gastric carcinoma localized at the antrum. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the surgically altered anatomy, diagnostic and therapeutic endoscopic retrograde cholangiopancreatography (ERCP) is more difficult in patients with previous Billroth II gastrectomy than in patients with native anatomy. The papillary area in the second part of the duodenum can only be reached through the afferent loop. As a result, the papilla of Vater appears upside-down compared with its orientation during standard ERCP. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Performing an ERCP in patients with Billroth II anatomy requires that the afferent loop be identified and entered, that the duodenal stump be reached, and that the papilla be cannulated. In many cases an endoscopic sphincterotomy is also performed. (See",
"      <a class=\"local\" href=\"#H17696948\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapeutic maneuvers that can be performed in the patient with unaltered gastroduodenal anatomy, such as stone extraction, drain insertion, and stent placement, are also feasible in patients with Billroth II anatomy once access to the bile duct has been obtained via endoscopic sphincterotomy or sphincteroplasty. All of these procedures should be performed by highly experienced endoscopists. (See",
"      <a class=\"local\" href=\"#H17696948\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Billroth II anatomy can increase the risk of complications. Perforation occurs more frequently in patients with Billroth II anatomy compared with patients with normal anatomy, and particular caution is required with the use of a side-viewing duodenoscope. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Choosing the appropriate endoscope'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/1\">",
"      Safrany L. Endoscopy and retrograde cholangio-pancreatography after Billroth II operation. Endoscopy 1972; 4:198.",
"     </a>",
"    </li>",
"    <li>",
"     Cremer M, Gulbis A, Toussaint J, et al. Techniques of endoscopic papillotomy. In: The Sphincter of Oddi, Demont JP (Ed), Springer-Verlag, Basel 1977.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/3\">",
"      Hintze RE, Adler A, Veltzke W, Abou-Rebyeh H. Endoscopic access to the papilla of Vater for endoscopic retrograde cholangiopancreatography in patients with billroth II or Roux-en-Y gastrojejunostomy. Endoscopy 1997; 29:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/4\">",
"      Hintze RE, Veltzke W, Adler A, Abou-Rebyeh H. Endoscopic sphincterotomy using an S-shaped sphincterotome in patients with a Billroth II or Roux-en-Y gastrojejunostomy. Endoscopy 1997; 29:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/5\">",
"      Prat F, Fritsch J, Choury AD, et al. Endoscopic sphincteroclasy: a useful therapeutic tool for biliary endoscopy in Billroth II gastrectomy patients. Endoscopy 1997; 29:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/6\">",
"      Kim MH, Lee SK, Lee MH, et al. Endoscopic retrograde cholangiopancreatography and needle-knife sphincterotomy in patients with Billroth II gastrectomy: a comparative study of the forward-viewing endoscope and the side-viewing duodenoscope. Endoscopy 1997; 29:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/7\">",
"      Demarquay JF, Dumas R, Buckley MJ, et al. Endoscopic retrograde cholangiopancreatography in patients with Billroth II gastrectomy. Ital J Gastroenterol Hepatol 1998; 30:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/8\">",
"      Aabakken L, Holthe B, Sandstad O, et al. Endoscopic pancreaticobiliary procedures in patients with a Billroth II resection: a 10-year follow-up study. Ital J Gastroenterol Hepatol 1998; 30:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/9\">",
"      Lin LF, Siauw CP, Ho KS, Tung JC. ERCP in post-Billroth II gastrectomy patients: emphasis on technique. Am J Gastroenterol 1999; 94:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/10\">",
"      Wang YG, Binmoeller KF, Seifert H, et al. A new guide wire papillotome for patients with Billroth II gastrectomy. Endoscopy 1996; 28:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/11\">",
"      Costamagna G, Mutignani M, Perri V, et al. Diagnostic and therapeutic ERCP in patients with Billroth II gastrectomy. Acta Gastroenterol Belg 1994; 57:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/12\">",
"      Faylona JM, Qadir A, Chan AC, et al. Small-bowel perforations related to endoscopic retrograde cholangiopancreatography (ERCP) in patients with Billroth II gastrectomy. Endoscopy 1999; 31:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/13\">",
"      Familiari P, Tringali A, Iacopini F, et al. ERCP in patients with prior Billroth II gastrectomy: Report of a two decades experience. Endoscopy 2005; 37:A280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/14\">",
"      Chahal P, Baron TH, Topazian MD, et al. Endoscopic retrograde cholangiopancreatography in post-Whipple patients. Endoscopy 2006; 38:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/15\">",
"      Law NM, Freeman ML. ERCP by using a prototype oblique-viewing endoscope in patients with surgically altered anatomy. Gastrointest Endosc 2004; 59:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/16\">",
"      Nakahara K, Horaguchi J, Fujita N, et al. Therapeutic endoscopic retrograde cholangiopancreatography using an anterior oblique-viewing endoscope for bile duct stones in patients with prior Billroth II gastrectomy. J Gastroenterol 2009; 44:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/17\">",
"      Kikuyama M, Sasada Y, Matsuhashi T, et al. ERCP afterRoux-en-Y reconstruction can be carried out using an oblique-viewing endoscope with an overtube. Dig Endosc 2009; 21:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/18\">",
"      Koo HC, Moon JH, Choi HJ, et al. The utility of a multibending endoscope for selective cannulation during ERCP in patients with a Billroth II gastrectomy (with video). Gastrointest Endosc 2009; 69:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/19\">",
"      Park CH, Lee WS, Joo YE, et al. Cap-assisted ERCP in patients with a Billroth II gastrectomy. Gastrointest Endosc 2007; 66:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/20\">",
"      Lee YT. Cap-assisted endoscopic retrograde cholangiopancreatography in a patient with a Billroth II gastrectomy. Endoscopy 2004; 36:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/21\">",
"      Costamagna G, Mutignani M, Gabbrielli A, et al. Endoscopic sphincterotomy in patients with Billroth II gastrectomy: improvements with a new inverted sphincterotome (abstract). Gastroenterology 1993; 104:A357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/22\">",
"      Osnes M, Rosseland AR, Aabakken L. Endoscopic retrograde cholangiography and endoscopic papillotomy in patients with a previous Billroth-II resection. Gut 1986; 27:1193.",
"     </a>",
"    </li>",
"    <li>",
"     Huibregtse K. Difficult cannulation in Billroth II gastrectomy patients. In: Endoscopic Biliary and pancreatic drainage, Thieme Verlag, Stuttgart - New York 1988. p.54.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/24\">",
"      Ricci E, Bertoni G, Conigliaro R, et al. Endoscopic sphincterotomy in Billroth II patients: an improved method using a diathermic needle as sphincterotome and a nasobiliary drain as guide. Gastrointest Endosc 1989; 35:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/25\">",
"      Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/26\">",
"      Cairns SR. Endoscopic balloon sphincteroplasty: use in a patient with a Billroth II gastrectomy. Endoscopy 1996; 28:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/27\">",
"      Dickey W, Jacob S, Porter KG. Balloon dilation of the papilla via a forward-viewing endoscope: an aid to therapeutic endoscopic retrograde cholangiopancreatography in patients with Billroth-II gastrectomy. Endoscopy 1996; 28:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/28\">",
"      Bergman JJ, van Berkel AM, Bruno MJ, et al. A randomized trial of endoscopic balloon dilation and endoscopic sphincterotomy for removal of bile duct stones in patients with a prior Billroth II gastrectomy. Gastrointest Endosc 2001; 53:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/29\">",
"      Ci&ccedil;ek B, Parlak E, Diibeyaz S, et al. Endoscopic retrograde cholangiopancreatography in patients with Billroth II gastroenterostomy. J Gastroenterol Hepatol 2007; 22:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/30\">",
"      Cremer M, Deviere J, Delhaye M, et al. Non-surgical management of severe chronic pancreatitis. Scand J Gastroenterol Suppl 1990; 175:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5415/abstract/31\">",
"      Costamagna G, Gabbrielli A, Mutignani M, et al. Extracorporeal shock wave lithotripsy of pancreatic stones in chronic pancreatitis: immediate and medium-term results. Gastrointest Endosc 1997; 46:231.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 676 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_18_5415=[""].join("\n");
var outline_f5_18_5415=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17696866\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CHOOSING THE APPROPRIATE ENDOSCOPE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17696848\">",
"      Forward-viewing versus side-viewing endoscopes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17696840\">",
"      Other endoscopes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17696948\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Entering the afferent loop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reaching the duodenal stump",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cannulating the papilla from the reverse position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Endoscopic sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17696866\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/676\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/676|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/46/28385\" title=\"figure 1\">",
"      Billroth II anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/20/18752\" title=\"figure 2\">",
"      Billroth II variations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/13/2261\" title=\"figure 3\">",
"      Total gastrectomy with reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/35/33329\" title=\"figure 4\">",
"      Roux en Y gastric bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/21/30036\" title=\"figure 5\">",
"      Biliary reconstruction with Roux-en-Y hepaticojejunostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/57/17303\" title=\"figure 6\">",
"      Conventional pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/43/5810\" title=\"figure 7\">",
"      Pylorus-preserving pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/53/19284\" title=\"figure 8\">",
"      Biliopancreatic diversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/18/7457\" title=\"figure 9\">",
"      Biliopancreatic diversion AGA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37831?source=related_link\">",
"      ERCP in patients with Roux-en-Y anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37175?source=related_link\">",
"      Endoscopic balloon dilatation for removal of bile duct stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24649?source=related_link\">",
"      Overview of deep small bowel enteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=related_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26216?source=related_link\">",
"      Post-ERCP bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=related_link\">",
"      Post-ERCP pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23959?source=related_link\">",
"      Post-ERCP septic complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/10/25767?source=related_link\">",
"      Precut (access) papillotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33688?source=related_link\">",
"      Role of surgery in the management of peptic ulcer disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_18_5416="Angiolupoid sarcoidosis";
var content_f5_18_5416=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71687%7EDERM%2F70564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71687%7EDERM%2F70564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Angiolupoid sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Angiolupoid sarcoidosis. Well demarcated, erythematous plaques on the cheek with numerous telangiectasias are characteristic of this clinical variant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Angiolupoid sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 212px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Well demarcated, erythematous plaques on the cheek with numerous telangiectasias are characteristic of this clinical variant of sarcoidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_18_5416=[""].join("\n");
var outline_f5_18_5416=null;
var title_f5_18_5417="Atypical antidepressants: Pharmacology, administration, and side effects";
var content_f5_18_5417=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Atypical antidepressants: Pharmacology, administration, and side effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/18/5417/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/18/5417/contributors\">",
"     Michael Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/18/5417/contributors\">",
"     Robert J Birnbaum, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/18/5417/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/18/5417/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/18/5417/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/18/5417/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/18/5417/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H20531374\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in understanding brain neurophysiology have led to the development of atypical antidepressants, including [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Agomelatine (not available in the United States)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       Bupropion",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       Mirtazapine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The atypical antidepressants are distinct from other classes of antidepressants that include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin modulators, tricyclics, and monoamine oxidase inhibitors (MAOIs). Atypical antidepressants are frequently used in patients with major depression who have inadequate responses or intolerable side effects during first-line treatment with selective serotonin reuptake inhibitors (SSRIs) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/2\">",
"     2",
"    </a>",
"    ]. However, atypical antidepressants are often first-line treatment if the drug has a desirable characteristic (eg, sexual side effects and weight gain occur less often with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    than SSRIs).",
"   </p>",
"   <p>",
"    The pharmacology, administration, and side effects of atypical antidepressants are reviewed here. Choosing a regimen for the initial treatment of depression and treatment of resistant depression is discussed separately, as are other antidepressant drug classes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link\">",
"       \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"       \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5129?source=see_link\">",
"       \"Serotonin modulators: Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link\">",
"       \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=see_link\">",
"       \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20533483\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28673666\">",
"    <span class=\"h2\">",
"     Drug-drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    may inhibit hepatic cytochrome P4502D6 enzymes that metabolize other medications and thereby cause drug-drug interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/3\">",
"     3",
"    </a>",
"    ]. By contrast, agomelatine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    do not moderately or potently inhibit P450 enzymes, and may thus be of benefit to depressed patients who are receiving other medications for general medical conditions. Specific interactions of atypical antidepressants with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20533490\">",
"    <span class=\"h2\">",
"     Guidelines to review with patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to prescribing atypical antidepressants, clinicians should discuss:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Drug interactions",
"     </li>",
"     <li>",
"      Side effects",
"     </li>",
"     <li>",
"      Time to response",
"     </li>",
"     <li>",
"      Stopping the medication",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Common and serious side effects and the need to take the medication as prescribed rather than on an as needed basis should be reviewed. Patients should also be informed that although some response may occur within the first two weeks of treatment, it may take many weeks (eg, 8 to 14) for a full response (severity of illness and co-morbid disease may affect how quickly depressed patients respond to treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20533497\">",
"    <span class=\"h2\">",
"     Medical tests and plasma levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific medical tests are required before starting atypical antidepressants. However, clinicians who prescribe agomelatine and wish to comply with recommendations from the European Medicines Agency should check liver function tests at baseline prior to initiating treatment, and then after 6, 12, and 24 weeks of treatment.",
"   </p>",
"   <p>",
"    Atypical antidepressant serum concentrations are not routinely monitored because they have not been shown to correlate with clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/5\">",
"     5",
"    </a>",
"    ]. However, levels can assess adherence and whether unresponsive patients are rapid metabolizers. Levels can also establish that it is safe to begin another serotonergic drug (eg, a monoamine oxidase inhibitor) after discontinuing an antidepressant that has serotonergic properties (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    ), in order to avoid the serotonin syndrome (",
"    <a class=\"graphic graphic_table graphicRef64604 \" href=\"UTD.htm?42/19/43324\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20533511\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest starting with the lowest minimal effective dose in order to avoid side effects and slowly increasing the dose as needed. Starting doses and target dose ranges of each atypical antidepressant are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef88065 \" href=\"UTD.htm?25/43/26300\">",
"     table 2",
"    </a>",
"    ). Depressed patients with comorbid anxiety disorders may tolerate the medication better by starting with half of the suggested dose. Doses are adjusted according to patient response, tolerability, and clinical urgency.",
"   </p>",
"   <p>",
"    Finding the effective dose of an antidepressant involves trial and error. After starting the drug and titrating up to the minimum effective dose, response should be monitored over the next two to four weeks. For patients who tolerate the antidepressant but do not respond, we continue titrating up the dose slowly (to avoid side effects) every two to four weeks. For unresponsive patients who do not tolerate the drug, we suggest switching to a different antidepressant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who recover from an episode of major depression should generally receive maintenance treatment with the full dose that successfully resolved the episode, rather than a lower dose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9850?source=see_link&amp;anchor=H8038660#H8038660\">",
"     \"Unipolar depression in adults: Continuation and maintenance treatment\", section on 'Dose'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85891814\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of pregnant women with antidepressants is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link\">",
"     \"Depression in pregnant women: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3491797\">",
"    <span class=\"h2\">",
"     Suicide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential effect of atypical antidepressants on suicidal ideation and behavior in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43783?source=see_link\">",
"     \"Effect of antidepressants on suicide risk in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20531439\">",
"    <span class=\"h1\">",
"     AGOMELATINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agomelatine is used to treat major depression, but is contraindicated in patients with liver disease and patients taking medications that are potent inhibitors of the liver cytochrome P450 enzyme 1A2. The drug is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20533252\">",
"    <span class=\"h2\">",
"     Pharmacology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agomelatine is a bicyclic naphthalenic compound whose structure resembles that of melatonin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Agomelatine acts as an agonist at melatonin receptors (MT1 and MT2) that are thought to provide beneficial effects upon sleep disturbances by helping to restore normal circadian rhythms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/8\">",
"     8",
"    </a>",
"    ]; patients with insomnia may thus prefer agomelatine [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The drug also antagonizes the serotonergic 5-HT2C receptor, which in turn enhances release of dopamine and norepinephrine. Agomelatine has no effect upon extracellular serotonin levels or monoamine uptake, and has no affinity for adrenergic, cholinergic, dopaminergic, and histaminergic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/6,7,10\">",
"     6,7,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pharmacokinetic parameters of agomelatine are displayed in the table (",
"    <a class=\"graphic graphic_table graphicRef88061 \" href=\"UTD.htm?2/55/2941\">",
"     table 3",
"    </a>",
"    ). Agomelatine is metabolized in the liver primarily by the P450 enzyme CYP1A2, and is contraindicated in patients taking medications that potently inhibit the enzyme. As an example, co-administration with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    has been demonstrated in vivo to raise agomelatine serum concentrations 60-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/10\">",
"     10",
"    </a>",
"    ]. Specific interactions of agomelatine with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"   </p>",
"   <p>",
"    The serum concentration of agomelatine may be lowered in heavy smokers, via induction of CYP1A2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20533259\">",
"    <span class=\"h2\">",
"     Administration, dose, and discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual starting dose of agomelatine for major depression is 25 mg per day at bedtime (",
"    <a class=\"graphic graphic_table graphicRef88065 \" href=\"UTD.htm?25/43/26300\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/5\">",
"     5",
"    </a>",
"    ]. For patients who do not respond after two to four weeks, the dose is increased to 50 mg per day.",
"   </p>",
"   <p>",
"    Abrupt discontinuation of agomelatine 25 mg per day does not cause withdrawal symptoms. In a randomized trial, 88 patients with major depression who remitted during 12 weeks of treatment with agomelatine 25 mg per day were assigned to continue treatment or to placebo for two weeks; the number of discontinuation symptoms was comparable for the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/11\">",
"     11",
"    </a>",
"    ]. However, for patients receiving agomelatine 50 mg per day, we suggest tapering the drug over one week, which is consistent with the preferred method of discontinuing any psychotropic medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20533266\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agomelatine may be hepatotoxic and is avoided in patients with active liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/12\">",
"     12",
"    </a>",
"    ]. A pooled analysis of randomized trials found that elevation of serum transaminases &gt;3 times the upper limit of normal was greater for agomelatine 50 mg per day than placebo (1.3 versus 0.3 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/13\">",
"     13",
"    </a>",
"    ]. Thus, the European Medicines Agency requires liver function tests at baseline; after 6, 12, and 24 weeks of treatment; and when clinically indicated thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other side effects are generally infrequent (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 4",
"    </a>",
"    ). In a pooled analysis of 13 randomized trials that compared agomelatine with placebo in 3034 patients with unipolar major depression, adverse effects that occurred more frequently with agomelatine included [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dizziness &ndash; 6 percent of patients who received agomelatine",
"     </li>",
"     <li>",
"      Insomnia &ndash; 3 percent",
"     </li>",
"     <li>",
"      Paresthesia &ndash; 1 percent",
"     </li>",
"     <li>",
"      Blurred vision &ndash; 1 percent",
"     </li>",
"     <li>",
"      Sinusitis &ndash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon randomized trials, agomelatine does not cause weight gain, gastrointestinal distress, cardiovascular toxicity, or sexual impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H296927\">",
"    <span class=\"h2\">",
"     Overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports of patients who overdosed on agomelatine describe epigastralgia, somnolence, fatigue, agitation, anxiety, tension, dizziness, cyanosis, or malaise [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/10\">",
"     10",
"    </a>",
"    ]. One patient ingested 2450 mg and recovered spontaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20531446\">",
"    <span class=\"h1\">",
"     BUPROPION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    is used to treat major depression, seasonal affective disorder, attention deficit hyperactivity disorder (ADHD), tobacco dependence, hypoactive sexual disorder, and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contraindications include bulimia nervosa, anorexia nervosa, use of monoamine oxidase inhibitors in the past two weeks, seizure disorders, and abrupt withdrawal from alcohol, benzodiazepines, or other sedatives. In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    should be used cautiously in patients receiving other drugs that can lower seizure threshold. Additional information about drug-drug interactions are discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H28673666\">",
"     'Drug-drug interactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20533287\">",
"    <span class=\"h2\">",
"     Pharmacology",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    is a monocyclic aminoketone that is structurally related to amphetamine [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/17\">",
"     17",
"    </a>",
"    ]. Some authorities classify the drug as a dopamine norepinephrine reuptake inhibitor, because it inhibits presynaptic reuptake of dopamine and norepinephrine (with a greater effect upon dopamine) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. The drug has little effect upon other neurotransmitters, and little to no affinity for postsynaptic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/17,19\">",
"     17,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pharmacokinetic parameters of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    are displayed in the table (",
"    <a class=\"graphic graphic_table graphicRef88061 \" href=\"UTD.htm?2/55/2941\">",
"     table 3",
"    </a>",
"    ). Bupropion is metabolized in the liver by the cytochrome P450 enzyme 2B6; medications that inhibit this enzyme may increase the plasma concentration of bupropion and thus raise the risk of seizure. Specific interactions of bupropion with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20533294\">",
"    <span class=\"h2\">",
"     Administration, dose, and discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    is available as three formulations that are bioequivalent and dosed as follows for major depression (",
"    <a class=\"graphic graphic_table graphicRef88065 \" href=\"UTD.htm?25/43/26300\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/16,17,20-22\">",
"     16,17,20-22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Immediate release",
"      </strong>",
"      &ndash; Typically started at 100 mg twice daily; for patients who do not respond after two to four weeks, the dose is increased to 100 mg three times daily. For patients who remain unresponsive after two to four weeks, the dose is increased to 150 mg three times daily. The maximum single dose is 150 mg.",
"     </li>",
"     <li>",
"      <strong>",
"       Sustained release",
"      </strong>",
"      &ndash; Typically started at 150 mg once daily; for unresponsive patients who do not respond after two to four weeks, the dose is increased to 150 mg twice daily. For patients who remain unresponsive after two to four weeks, the dose is increased to 200 mg twice daily. The maximum single dose is 200 mg. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Extended release",
"      </strong>",
"      &ndash; Typically started at 150 mg once daily; for unresponsive patients who do not respond after two to four weeks, the dose is increased to 300 mg once daily. For patients who remain unresponsive after two to four weeks, the dose is increased to 450 mg daily. The maximum single dose in the United States is 450 mg and in Europe is 300 mg per day. The extended release formulation is intended to be swallowed whole and not divided, crushed, or chewed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In clinically urgent situations such as inpatient treatment, the dose of each formulation can be titrated up after three days. For patients with renal or hepatic impairment, we generally decrease the dose by at least 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There appear to be no significant withdrawal symptoms upon discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    . Nevertheless, we taper the drug over one to two weeks before stopping it, which is consistent with the preferred method of discontinuing any psychotropic medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20533301\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures may occur with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    and the incidence appears to be correlated with dose. The rate with the [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/16,22\">",
"     16,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate release formulation at doses of 300 to 450 mg per day is 0.4 percent; however, the incidence increases approximately 10 fold at higher doses of up to 600 mg per day &nbsp;",
"     </li>",
"     <li>",
"      Sustained release formulation (which allows for lower peak plasma concentrations) at doses of 100 to 300 mg per day is 0.1 percent, and at 400 mg per day is 0.4 percent",
"     </li>",
"     <li>",
"      Extended release formulation at doses &le;450 mg per day is 0.1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By comparison, the estimated rate of seizures in patients treated with selective serotonin reuptake inhibitors (SSRIs) is 0.1 percent, tricyclics 0.4 to 2 percent, and in the general population is 0.07 to 0.09 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/23\">",
"     23",
"    </a>",
"    ]. Seizures appear to be especially problematic in patients with bulimia nervosa or anorexia nervosa, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    is contraindicated in these patients; a randomized trial in which the drug was given to 55 nondepressed patients with bulimia nervosa found that generalized tonic-clonic seizures occurred in 4 (7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    can cause several other side effects (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 4",
"    </a>",
"    ). A pooled analysis of four randomized trials compared bupropion extended release (300 to 450 mg per day) with placebo in 991 patients with major depression for 8 or 12 weeks; adverse effects that occurred at least twice as often with bupropion than placebo included [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dry mouth &ndash; 21 percent of patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"     </li>",
"     <li>",
"      Nausea &ndash; 13 percent",
"     </li>",
"     <li>",
"      Insomnia &ndash; 12 percent",
"     </li>",
"     <li>",
"      Dizziness &ndash; 10 percent",
"     </li>",
"     <li>",
"      Anxiety &ndash; 6 percent",
"     </li>",
"     <li>",
"      Dyspepsia &ndash; 6 percent",
"     </li>",
"     <li>",
"      Sinusitis &ndash; 5 percent",
"     </li>",
"     <li>",
"      Tremor &ndash; 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common side effects (eg, dry mouth, nausea, and insomnia) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    extended release are similar to those of the other two formulations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/15,25\">",
"     15,25",
"    </a>",
"    ]. However, the relative tolerability of the different formulations has not been directly compared.",
"   </p>",
"   <p>",
"    Weight loss can occur with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    . A meta-analysis found that patients lost approximately 1 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/26\">",
"     26",
"    </a>",
"    ]. As an example, an eight week randomized trial in 274 patients with unipolar major depression found that bupropion extended release (300 or 450 mg per day) led to a mean weight loss of 1.1 kg, whereas placebo led to a mean weight increase of 0.2 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    may be preferred by patients who want to minimize the risk of antidepressant-induced sexual dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Two randomized trials compared bupropion extended release (300 or 450 mg per day),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    (10 or 20 mg per day), and placebo for eight weeks in 830 patients with unipolar major depression and normal sexual functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/32\">",
"     32",
"    </a>",
"    ]. Worsened sexual functioning was comparable for patients who received bupropion or placebo (20 and 15 percent), but higher with escitalopram than bupropion (36 versus 20 percent). In addition, depressed patients with sexual dysfunction induced by SSRIs may find that adjunctive bupropion at a target dose of 300 mg per day can improve desire and frequency of sexual activity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients may notice",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    is mildly stimulating, which may be interpreted as anxiety and can lead to insomnia if given before bedtime. This stimulant-like effect may be beneficial in depressed patients with fatigue, hypersomnia, or poor concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    has minimal effects upon blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/27,34\">",
"     27,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For many drugs, side effects are associated with peak plasma concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/16\">",
"     16",
"    </a>",
"    ]. The once daily extended release and twice daily sustained release formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    reduce the number of exposures to peak concentrations, compared with the thrice daily immediate release formulation. Discontinuation of treatment due to side effects in randomized trials was greater for bupropion sustained release than placebo, and comparable for extended release and placebo:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a pooled analysis of three trials that compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      sustained release (100 to 400 mg per day) with placebo for eight weeks in 1420 patients with major depression, discontinuation of treatment due to side effects occurred in more patients who received bupropion than placebo (7 versus 4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A pooled analysis of five randomized trials that compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      extended release (150 to 450 mg per day) with placebo for eight weeks in 1597 patients with major depression found that discontinuation of treatment due to side effects was comparable with bupropion and placebo (5 versus 4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H296934\">",
"    <span class=\"h2\">",
"     Overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overdose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    can cause seizures, hypertension, tachycardia, arrhythmias, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/15,35\">",
"     15,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20531453\">",
"    <span class=\"h1\">",
"     MIRTAZAPINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     Mirtazapine",
"    </a>",
"    is used to treat major depression, generalized anxiety disorder, and tension type headaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20533322\">",
"    <span class=\"h2\">",
"     Pharmacology",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     Mirtazapine",
"    </a>",
"    is a piperazinoazepine compound that has a tetracyclic structure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. However, the drug is not related to the tetracyclic antidepressant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/18/16678?source=see_link\">",
"     maprotiline",
"    </a>",
"    , which is classified with the tricyclic antidepressants because it blocks reuptake of serotonin and norepinephrine. By contrast, mirtazapine is not a reuptake inhibitor, and some authorities classify mirtazapine as a noradrenergic and specific serotonergic antidepressant because it antagonizes presynaptic alpha-2 adrenergic receptors and postsynaptic serotonin 5-HT2 and serotonin 5-HT3 receptors. Blockade of the adrenergic receptors increases release of norepinephrine and serotonin. Blockade of the serotonergic receptors increases neurotransmission mediated by serotonin 5-HT1 receptors. In addition, mirtazapine has a high affinity for histamine H1 receptors (which probably accounts for the drug&rsquo;s sedative properties). Mirtazapine has low affinity for cholinergic, alpha-1 adrenergic, and dopaminergic receptors.",
"   </p>",
"   <p>",
"    The pharmacokinetic parameters of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    are displayed in the table (",
"    <a class=\"graphic graphic_table graphicRef88061 \" href=\"UTD.htm?2/55/2941\">",
"     table 3",
"    </a>",
"    ). Drug-drug interactions with mirtazapine are generally not a problem because the drug is not a potent or moderate inhibitor of hepatic cytochrome P450 enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20533329\">",
"    <span class=\"h2\">",
"     Administration, dose, and discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    for major depression is 15 mg at bedtime (",
"    <a class=\"graphic graphic_table graphicRef88065 \" href=\"UTD.htm?25/43/26300\">",
"     table 2",
"    </a>",
"    ). For patients who do not respond after two to four weeks, the dose is increased to 30 mg at bedtime. For patients who remain depressed after two to four weeks, the dose is increased to the maximum dose of 45 mg at bedtime. The dose can be titrated up more quickly in clinically urgent situations (eg, inpatient treatment), by 15 mg increments every week. For patients with severe renal (creatinine clearance &lt;40",
"    <span class=\"nowrap\">",
"     mL/minute)",
"    </span>",
"    or hepatic impairment, we generally limit the dose to 30 mg per day due to decreased clearance of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between the dose and side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    is unusual, in that sedation appears more pronounced at doses of 15 mg daily than at doses &ge;30 mg daily; this may be due to increased noradrenergic neurotransmission as the dose is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/37\">",
"     37",
"    </a>",
"    ]. Dosing may be initiated at 30 mg or more in order to reduce sedation. It is not clear whether side effects other than sedation are reduced at higher doses (30 or 45 mg per day).",
"   </p>",
"   <p>",
"    The drug is available as an oral, rapidly dissolving tablet, which can be useful for patients with swallowing difficulties and gastrointestinal disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abrupt discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    can cause dizziness, abnormal dreams, paresthesias, agitation, anxiety, fatigue, confusion, headache, tremor, nausea, vomiting, and sweating [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, we suggest that doses of 30 to 45 mg per day be tapered over one to two weeks to a dose of 15 mg per day for one week prior to discontinuation. Additional information about the discontinuation syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link&amp;anchor=H12#H12\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\", section on 'Discontinuation of antidepressants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20533336\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     Mirtazapine",
"    </a>",
"    can cause several side effects (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 4",
"    </a>",
"    ). A pooled analysis of randomized trials that compared mirtazapine with placebo for six weeks in 814 patients with major depression found that discontinuation of treatment due to side effects for mirtazapine was 16 percent and for placebo 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/36,38\">",
"     36,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of specific side effects was examined in a pooled analysis of randomized trials that included 1726 patients with major depression; adverse effects that occurred more frequently with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    than placebo included [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dry mouth &ndash; 25 percent of patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"     </li>",
"     <li>",
"      Drowsiness &ndash; 23 percent",
"     </li>",
"     <li>",
"      Sedation &ndash; 19 percent",
"     </li>",
"     <li>",
"      Appetite increased &ndash; 11 percent",
"     </li>",
"     <li>",
"      Weight increased &ndash; 10 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sexual dysfunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    and placebo appear to be comparable, based upon a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, changes in blood pressure and pulse are comparable for mirtazapine and placebo, based upon a pooled analysis of randomized patients with major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     Mirtazapine",
"    </a>",
"    may possibly cause agranulocytosis and neutropenia in rare instances [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/36,39\">",
"     36,39",
"    </a>",
"    ]. However, we do not routinely monitor white blood cell counts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H296941\">",
"    <span class=\"h2\">",
"     Overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overdose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    is generally benign, based upon:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A five year retrospective study of 117 patients who overdosed on the drug (median dose 450 mg). Tachycardia occurred in 30 percent and reduced level of consciousness in 27 percent; however, there were no clinically significant electrocardiogram (ECG) changes, nor were there any seizures [",
"      <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A two year retrospective study of 29 patients who deliberately or accidentally overdosed on the drug (mean dose 594 mg, maximum 1500 mg) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/18/5417/abstract/41\">",
"       41",
"      </a>",
"      ]. None of the patients suffered arrhythmias or seizures, and none required admission to a critical care facility for airway management or ventilatory support.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"       \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"       \"Patient information: Depression in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The National Institute of Mental Health also has educational material on the use of antidepressants, including SSRIs, entitled, \"What medications are used to treat depression?\" that is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/mental-health-medications/what-medications-are-used-to-treat-depression.shtml\">",
"     file://www.nimh.nih.gov/health/publications/mental-health-medications/what-medications-are-used-to-treat-depression.shtml",
"    </a>",
"    . Material explaining the symptoms, causes, and treatment for depression is also available in a booklet entitled \"Depression\" that is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/depression/index.shtml\">",
"     file://www.nimh.nih.gov/health/publications/depression/index.shtml",
"    </a>",
"    . Both publications can also be obtained through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.",
"   </p>",
"   <p>",
"    The Depression and Bipolar Support Alliance (",
"    <a class=\"external\" href=\"file://www.dbsalliance.org/\">",
"     file://www.dbsalliance.org",
"    </a>",
"    &nbsp;or 800-826-3632) is a national organization whose mission is to educate members about depression and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.",
"   </p>",
"   <p>",
"    The National Alliance on Mental Illness (",
"    <a class=\"external\" href=\"file://www.nami.org/\">",
"     file://www.nami.org",
"    </a>",
"    &nbsp;or 800-950-6264) is a similarly structured organization devoted to providing education, support, and advocacy for patients with any mental illness. Depression is one of their priorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20531545\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atypical antidepressants include agomelatine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      . These drugs can be used for the initial treatment of major depression, as well as patients with treatment resistant depression or other disorders. (See",
"      <a class=\"local\" href=\"#H20531374\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The pharmacokinetic parameters of atypical antidepressants are presented in the table (",
"      <a class=\"graphic graphic_table graphicRef88061 \" href=\"UTD.htm?2/55/2941\">",
"       table 3",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       Bupropion",
"      </a>",
"      may inhibit the hepatic enzyme CYP2D6. (See",
"      <a class=\"local\" href=\"#H28673666\">",
"       'Drug-drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to prescribing atypical antidepressants, clinicians should discuss drug interactions, side effects (",
"      <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"       table 4",
"      </a>",
"      ), time to response, and stopping the medication. No specific medical tests are required before starting atypical antidepressants and drug plasma levels are not routinely performed. (See",
"      <a class=\"local\" href=\"#H20533483\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest starting with the lowest minimal effective dose in order to avoid side effects and slowly increasing the dose in unresponsive patients. Starting doses and target dose ranges of each atypical antidepressant are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef88065 \" href=\"UTD.htm?25/43/26300\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20533511\">",
"       'Dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Agomelatine is contraindicated in patients with liver disease and patients taking medications that are potent inhibitors of the liver cytochrome P450 enzyme 1A2. Adverse effects include dizziness. The drug is not available in the United States. (See",
"      <a class=\"local\" href=\"#H20531439\">",
"       'Agomelatine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      include seizures, dry mouth, nausea, insomnia, dizziness, anxiety, dyspepsia, sinusitis, and tremor. (See",
"      <a class=\"local\" href=\"#H20531446\">",
"       'Bupropion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      include dry mouth, drowsiness, sedation, appetite increase, and weight increase. (See",
"      <a class=\"local\" href=\"#H20531453\">",
"       'Mirtazapine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/1\">",
"      Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998; 51:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/2\">",
"      Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354:1231.",
"     </a>",
"    </li>",
"    <li>",
"     Wynn GH, Sandson N, Muniz J. Psychiatry. In: Clinical Manual of Drug Interaction Principles for Medical Practice, Wynn GH, Oesterheld JR, Cozza KL, Armstrong SC.  (Eds), American Psychiatric Publishing, Inc., Washington, DC 2009. p.423.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/4\">",
"      Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/5\">",
"      McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol 2010; 25:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/6\">",
"      Green B. Focus on agomelatine. Curr Med Res Opin 2011; 27:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/7\">",
"      Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011; 378:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/8\">",
"      Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010; 71:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/9\">",
"      Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68:1723.",
"     </a>",
"    </li>",
"    <li>",
"     Electronic medicines compendium. file://www.medicines.org.uk/ (Accessed on July 31, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/11\">",
"      Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/12\">",
"      Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf 2011; 34:709.",
"     </a>",
"    </li>",
"    <li>",
"     European Medicines Agency. CHMP Assessment report for Valdoxan. file://www.ema.europa.eu/ (Accessed on July 31, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/14\">",
"      Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010; 24:479.",
"     </a>",
"    </li>",
"    <li>",
"     Clayton AH, Gillespie EH. Bupropion. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB.  (Eds), American Psychiatric Publishing, Inc., Washington, DC 2009. p.415.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/16\">",
"      Fava M, Rush AJ, Thase ME, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005; 7:106.",
"     </a>",
"    </li>",
"    <li>",
"     Labbate LA, Fava M, Rosenbaum JF, Arana GW. Drugs for the treatment of depression. In: Handbook of Psychiatric Drug Therapy, Sixth Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.54.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/18\">",
"      Dhillon S, Yang LP, Curran MP. Spotlight on bupropion in major depressive disorder. CNS Drugs 2008; 22:613.",
"     </a>",
"    </li>",
"    <li>",
"     Janicak PG, Marder SR, Pavuluri MN. Treatment with antidepressants. In: Principles and Practice of Psychopharmacotherapy, Fifth Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.199.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/20\">",
"      Gartlehner G, Thaler K, Hill S, Hansen RA. How should primary care doctors select which antidepressants to administer? Curr Psychiatry Rep 2012; 14:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/21\">",
"      Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther 2005; 27:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/22\">",
"      Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs 2008; 68:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/23\">",
"      Montgomery SA. Antidepressants and seizures: emphasis on newer agents and clinical implications. Int J Clin Pract 2005; 59:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/24\">",
"      Horne RL, Ferguson JM, Pope HG Jr, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry 1988; 49:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/25\">",
"      Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther 1999; 21:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/26\">",
"      Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/27\">",
"      Jefferson JW, Rush AJ, Nelson JC, et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006; 67:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/28\">",
"      Gartlehner G, Hansen RA, Reichenpfader U, et al. Drug Class Review: Second-Generation Antidepressants: Final Update 5 Report [Internet]. Drug Class Reviews 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/29\">",
"      Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/30\">",
"      Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005; 66:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/31\">",
"      Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009; 29:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/32\">",
"      Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006; 67:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/33\">",
"      Clayton AH, Warnock JK, Kornstein SG, et al. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 2004; 65:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/34\">",
"      Thase ME, Haight BR, Johnson MC, et al. A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. J Clin Psychopharmacol 2008; 28:302.",
"     </a>",
"    </li>",
"    <li>",
"     DrugBank file://www.drugbank.ca/ (Accessed on July 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/36\">",
"      Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs 2009; 23:427.",
"     </a>",
"    </li>",
"    <li>",
"     Schatzberg AF. Mirtazapine. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB.  (Eds), American Psychiatric Publishing, Inc., Washington, DC 2009. p.429.",
"    </li>",
"    <li>",
"     Mirtazapine product information. file://www.merck.com/ (Accessed on August 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/39\">",
"      Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995; 10 Suppl 4:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/40\">",
"      Waring WS, Good AM, Bateman DN. Lack of significant toxicity after mirtazapine overdose: a five-year review of cases admitted to a regional toxicology unit. Clin Toxicol (Phila) 2007; 45:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5417/abstract/41\">",
"      Kelly CA, Dhaun N, Laing WJ, et al. Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol 2004; 42:67.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85816 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-0E8BE10A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_18_5417=[""].join("\n");
var outline_f5_18_5417=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20531545\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20531374\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20533483\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28673666\">",
"      Drug-drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20533490\">",
"      Guidelines to review with patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20533497\">",
"      Medical tests and plasma levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20533511\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85891814\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3491797\">",
"      Suicide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20531439\">",
"      AGOMELATINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20533252\">",
"      Pharmacology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20533259\">",
"      Administration, dose, and discontinuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20533266\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H296927\">",
"      Overdose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20531446\">",
"      BUPROPION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20533287\">",
"      Pharmacology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20533294\">",
"      Administration, dose, and discontinuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20533301\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H296934\">",
"      Overdose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20531453\">",
"      MIRTAZAPINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20533322\">",
"      Pharmacology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20533329\">",
"      Administration, dose, and discontinuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20533336\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H296941\">",
"      Overdose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20531545\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/85816\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/85816|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/19/43324\" title=\"table 1\">",
"      Serotonin syndrome drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/43/26300\" title=\"table 2\">",
"      Atypical antidepressants - Doses for treating depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/55/2941\" title=\"table 3\">",
"      Atypical antidepressants - Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/46/38639\" title=\"table 4\">",
"      Side effects antidepressants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=related_link\">",
"      Antidepressant medication in adults: Switching and discontinuing medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43783?source=related_link\">",
"      Effect of antidepressants on suicide risk in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=related_link\">",
"      Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=related_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5129?source=related_link\">",
"      Serotonin modulators: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9850?source=related_link\">",
"      Unipolar depression in adults: Continuation and maintenance treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_18_5418="Evaluation of subacute and chronic cough in adults";
var content_f5_18_5418=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of subacute and chronic cough in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/18/5418/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/18/5418/contributors\">",
"     Ronald C Silvestri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/18/5418/contributors\">",
"     Steven E Weinberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/18/5418/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/18/5418/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/18/5418/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/18/5418/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/18/5418/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/18/5418/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptom of cough, which is responsible for approximately 30 million clinician visits annually in the United States, is one of the most common symptoms for which outpatient care is sought [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/1\">",
"     1",
"    </a>",
"    ]. In an outpatient pulmonary practice, evaluation and management of persistent cough can account for up to 40 percent of the practice volume [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cough can be classified based upon the duration of the cough; within each category are likely diagnostic possibilities. Acute cough exists for less than three weeks and is most commonly due to an acute respiratory tract infection. Other considerations include an acute exacerbation of underlying chronic pulmonary disease, pneumonia, and pulmonary embolism.",
"   </p>",
"   <p>",
"    Cough that has been present longer than three weeks is either subacute (three to eight weeks) or chronic (more than eight weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients who seek medical attention for chronic cough are more likely to be female [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Among patients with chronic cough, women tend to cough more often and to have heightened cough reflex sensitivity compared to men [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The common etiologies, complications, and evaluation of subacute and chronic cough will be reviewed here. The treatment of subacute and chronic cough is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27913?source=see_link\">",
"     \"Treatment of subacute and chronic cough in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COUGH REFLEX ARC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each cough occurs through the stimulation of a complex reflex arc. This is initiated by the irritation of cough receptors that exist not only in the epithelium of the upper and lower respiratory tracts, but also in the pericardium, esophagus, diaphragm, and stomach. Chemical receptors sensitive to acid, cold, heat,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    -like compounds, and other chemical irritants trigger the cough reflex via activation of ion channels of the transient receptor potential vanilloid type 1 (TRPV1) and transient receptor potential ankyrin type 1 (TRPA1) classes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10186?source=see_link&amp;anchor=H13#H13\">",
"     \"Neuronal control of the airways\", section on 'Reflex regulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mechanical cough receptors can be stimulated by triggers such as touch or displacement. Laryngeal and tracheobronchial receptors respond to both mechanical and chemical stimuli.",
"   </p>",
"   <p>",
"    Impulses from stimulated cough receptors traverse an afferent pathway via the vagus nerve to a \"cough center\" in the medulla, which itself may be under some control by higher cortical centers. Sex-related differences in cough reflex sensitivity explain the observation that women are more likely than men to develop chronic cough [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/1,11-13\">",
"     1,11-13",
"    </a>",
"    ]. The cough center generates an efferent signal that travels down the vagus, phrenic, and spinal motor nerves to expiratory musculature to produce the cough (",
"    <a class=\"graphic graphic_figure graphicRef55232 \" href=\"UTD.htm?33/15/34046\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common etiologies of chronic cough are upper airway cough syndrome (due to postnasal drip), asthma, and gastroesophageal reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/1-3,14-18\">",
"     1-3,14-18",
"    </a>",
"    ]. However, a number of other important etiologies must also be considered in patients presenting with persistent cough. As an example, a post-infectious etiology is a particularly common cause of subacute cough, with the cough often lingering long after the other acute symptoms of the infection have dissipated. One study showed that in nearly half of patients, subacute cough was post infectious and resolved without specific therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cough may also be a complication of drug therapy, particularly with angiotensin converting enzyme (ACE) inhibitors.",
"   </p>",
"   <p>",
"    Other less common causes of chronic cough include a number of disorders affecting the airways (nonasthmatic eosinophilic bronchitis, chronic bronchitis, bronchiectasis, neoplasm, foreign body) or the pulmonary parenchyma (interstitial lung disease, lung abscess) (",
"    <a class=\"graphic graphic_table graphicRef57282 \" href=\"UTD.htm?17/58/18347\">",
"     table 1",
"    </a>",
"    ). A cause is identified in 75 to 90 percent of patients with chronic cough [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/2,14,16\">",
"     2,14,16",
"    </a>",
"    ]. However, some patients may experience chronic cough of unclear etiology for years, despite extensive evaluation. The etiology of so-called \"chronic idiopathic cough\" is unknown; exaggerated cough reflex sensitivity has been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/5,20\">",
"     5,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Upper airway cough syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies suggest that upper airway cough syndrome related to postnasal drip is a common cause of subacute and chronic cough [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/2,3,16,19\">",
"     2,3,16,19",
"    </a>",
"    ]. Underlying reasons for postnasal drip include allergic, perennial nonallergic, and vasomotor rhinitis; acute nasopharyngitis; and sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/21\">",
"     21",
"    </a>",
"    ]. Once secretions are present in the upper airway, cough is probably induced by stimulation of cough receptors within the laryngeal mucosa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link\">",
"     \"An overview of rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms of postnasal drip include frequent nasal discharge, a sensation of liquid dripping into the back of the throat, and frequent throat clearing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/2\">",
"     2",
"    </a>",
"    ]. However, postnasal drip may also be \"silent,\" so that the absence of these symptoms does not necessarily exclude the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/16\">",
"     16",
"    </a>",
"    ]. Clues on physical examination are a cobblestone appearance to the nasopharyngeal mucosa and the presence of secretions in the nasopharynx.",
"   </p>",
"   <p>",
"    Because the symptoms and signs of postnasal drip are nonspecific, there are no definitive criteria for its diagnosis, and it is ultimately the response to therapy that secures the diagnosis. When an alternative specific cause for cough is not apparent, empiric therapy of postnasal drip should be attempted before embarking on an extensive diagnostic work-up for other etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/1\">",
"     1",
"    </a>",
"    ]. Radiographic evidence of mucosal thickening is a relatively nonspecific finding, and radiographic studies generally are not indicated unless empiric treatment of chronic rhinitis has failed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma is the second leading cause of persistent cough in adults, and the most common cause in children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/23\">",
"     23",
"    </a>",
"    ]. Cough due to asthma is commonly accompanied by episodic wheezing and dyspnea; however, it can also be the sole manifestation of a form of asthma called \"cough variant asthma\" [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Cough variant asthma can progress to include wheezing and dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A diagnosis of asthma is suggested when the patient is atopic or has a family history of asthma. Asthma-related cough may be seasonal, may follow an upper respiratory tract infection, or may worsen upon exposure to cold, dry air, dust, mold, or to certain fumes or fragrances. A cough accompanied by wheezing or dyspnea, or one that occurs following initiation of beta-blocker therapy also suggests asthma.",
"   </p>",
"   <p>",
"    In some cases, the cough is accompanied by reversible airflow obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/28\">",
"     28",
"    </a>",
"    ]. In other patients, baseline spirometry is normal, but airways hyperreactivity can be demonstrated by bronchoprovocation testing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/14,24\">",
"     14,24",
"    </a>",
"    ]. However, in a patient with persistent cough, the presence of reversible airflow obstruction or a positive bronchoprovocation test does not necessarily prove that the cough is secondary to asthma. One study, for example, evaluated the utility of spirometry pre- and post-bronchodilator in predicting that asthma was responsible for cough [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/2\">",
"     2",
"    </a>",
"    ]. Spirometry was falsely positive in 33 percent of patients, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    challenge was falsely positive in 22 percent. Thus, the best way to confirm asthma as a cause of cough is to demonstrate improvement in the cough with appropriate therapy for asthma (eg, two to four weeks of inhaled glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/29\">",
"     29",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Patients with active asthma typically have eosinophilic bronchitis. The diagnosis of nonasthmatic eosinophilic bronchitis should be considered in atopic patients with an idiopathic chronic cough and sputum eosinophilia in the absence of airway hyperreactivity. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Nonasthmatic eosinophilic bronchitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Exhaled nitric oxide (NO) has been studied as a predictor of response to inhaled glucocorticoids in both asthma and in nonasthmatic eosinophilic bronchitis. Exhaled NO and sputum eosinophilia are correlated in these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/30\">",
"     30",
"    </a>",
"    ]. However, some studies have shown exhaled NO to be a good predictor of response of chronic cough to inhaled steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/31\">",
"     31",
"    </a>",
"    ], while other studies have not [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/32\">",
"     32",
"    </a>",
"    ]. The explanation for this discrepancy may in part be related to what value is chosen to reflect an abnormally elevated exhaled NO.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gastroesophageal reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroesophageal reflux is often reported to be the second or third most common cause of persistent cough [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/1,2,14,16\">",
"     1,2,14,16",
"    </a>",
"    ], although it is the most common cause in some reports, occurring in 30 to 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/17,33\">",
"     17,33",
"    </a>",
"    ]. Many patients complain of symptoms of gastroesophageal reflux (heartburn or a sour taste in the mouth); however, these symptoms are absent in more than 40 percent of patients in whom cough is due to reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/2,14,34,35\">",
"     2,14,34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several factors are potentially responsible for the cough associated with gastroesophageal reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stimulation of receptors in the upper respiratory tract (eg, in the larynx).",
"     </li>",
"     <li>",
"      Aspiration of gastric contents, leading to stimulation of receptors in the lower respiratory tract.",
"     </li>",
"     <li>",
"      An esophageal-tracheobronchial cough reflex induced by reflux of acid into the distal esophagus. In one study of patients with chronic cough and reflux, infusion of acid into the distal esophagus significantly increased cough frequency [",
"      <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/38\">",
"       38",
"      </a>",
"      ]. This effect was absent in control subjects without chronic cough. The acid-induced cough was significantly decreased by pretreatment with either inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      or a topical anesthetic (lignocaine) instilled into the esophagus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of cough induced by gastroesophageal reflux may be suggested by an abnormal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow, but this study is negative in the majority of patients and many patients with reflux do not have cough [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/2\">",
"     2",
"    </a>",
"    ]. Prolonged (24 hour) esophageal pH monitoring, ideally performed with event markers to allow correlation of cough with esophageal pH, is generally considered the optimal diagnostic study, with a sensitivity exceeding 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/1,2,14,35\">",
"     1,2,14,35",
"    </a>",
"    ]. However, even with maximal antireflux therapy, some patients with positive results on esophageal pH monitoring continue to cough [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Esophageal dysmotility, with or without evidence of GERD, appears to be common in patients with chronic cough. However the role of esophageal manometry in the evaluation remains to be defined [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastroesophageal reflux can also contribute to asthma symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39816?source=see_link\">",
"     \"Gastroesophageal reflux and asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Laryngopharyngeal reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngopharyngeal reflux (LPR) is the retrograde movement of gastric contents (acid and enzymes such as pepsin) into the laryngopharynx leading to symptoms referable to the",
"    <span class=\"nowrap\">",
"     larynx/hypopharynx",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/43\">",
"     43",
"    </a>",
"    ]. Most patients are relatively unaware of LPR with only 35 percent reporting heartburn. Typical LPR symptoms include",
"    <span class=\"nowrap\">",
"     dysphonia/hoarseness,",
"    </span>",
"    chronic cough, mild dysphagia and nonproductive throat clearing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33960?source=see_link\">",
"     \"Laryngopharyngeal reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    LPR is seen as primarily an upper esophageal sphincter (UES) problem that mainly occurs in the upright position during periods of physical exertion (eg, bending over, Valsalva, exercise). In contrast, GERD is felt to be a problem of the lower esophageal sphincter and mainly occurs in a recumbent position. There appears to be a lower incidence of esophageal dysmotility in LPR versus GERD.",
"   </p>",
"   <p>",
"    Direct laryngoscopic evaluation can assist in the diagnosis of cough from reflux. Arytenoid erythema and edema and pharyngeal inflammation often suggest laryngeal and pharyngeal reflux, and when seen, suggest that a course of treatment for reflux is indicated with monitoring of the cough on such therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Respiratory tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cough following viral or other upper respiratory tract infection can persist for more than eight weeks after the acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/44\">",
"     44",
"    </a>",
"    ]. Such cases increase in frequency during outbreaks of Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Bordetella pertussis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/1,45,46\">",
"     1,45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29289?source=see_link\">",
"     \"Acute bronchitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several possibly interrelated mechanisms may be responsible for cough in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secretions from a postnasal drip may stimulate receptors in the upper respiratory tract. Antihistamine-decongestant therapy may be effective in reducing nasal discharge, nasal obstruction, throat clearing, and cough [",
"      <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Enhanced sensitivity of airway nerves, assessed experimentally by the concentration of inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      required to elicit cough, may be present after upper respiratory tract infections, particularly in those patients who develop a nonproductive cough [",
"      <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/48\">",
"       48",
"      </a>",
"      ]. A possible explanation for this response is exposure of afferent nerves, located immediately below epithelial tight junctions, as a consequence of viral-induced epithelial necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Airway inflammation following acute viral respiratory infections is associated with airway hyperresponsiveness and the potential for cough as well as airway constriction [",
"      <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pertussis is a common, but under recognized, cause of persistent cough in adolescents and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/51\">",
"     51",
"    </a>",
"    ]. In the United States, the recognition of pertussis in adolescents and adults has increased dramatically over the past decade [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In one series of 75 adults with cough lasting more than two weeks, 21 percent met serologic criteria for pertussis infection despite a negative culture for Bordetella pertussis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/54\">",
"     54",
"    </a>",
"    ]. However, accurate serologic studies are infrequently available and may be difficult to interpret, further complicating confirmation of this diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients appear to have unsuspected bacterial suppurative disease of the large airways, in the absence of bronchiectasis, as a cause of chronic cough. Bronchoscopic evaluation and microbiologic sampling of the airways led to this diagnosis in a series of 15 patients undergoing evaluation at a single center for cough that remained unexplained after extensive evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/57\">",
"     57",
"    </a>",
"    ]. While four of these patients had underlying systemic disease, the remainder had no evidence of immune compromise. Aggressive antibiotic therapy, based upon the results of bronchoscopic culture, led to improvement or elimination of the cough in all patients. The prevalence of this disorder, and the appropriate duration of antibiotic therapy, remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nonproductive cough is a well-recognized complication of treatment with angiotensin converting enzyme (ACE) inhibitors, occurring in up to 15 percent of patients treated with these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/13,58\">",
"     13,58",
"    </a>",
"    ]. Although the pathogenesis of the cough is not known with certainty, it has commonly been hypothesized that accumulation of bradykinin, which is normally degraded in part by ACE, may stimulate afferent C-fibers in the airway [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link&amp;anchor=H6#H6\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Cough'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The important observation that cough does",
"    <strong>",
"     not",
"    </strong>",
"    appear to occur with increased frequency in patients treated with angiotensin II receptor antagonists (which do not increase kinin levels) is consistent with the kinin hypothesis. A review of clinical trials found that the incidence of cough with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    was similar to that with placebo (3 to 3.4 percent) and well below that seen with ACE inhibitors (10.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/60\">",
"     60",
"    </a>",
"    ]. Another large study evaluated patients with a prior history of ACE inhibitor-induced cough; the incidence of recurrent cough was much higher with readministration of an ACE inhibitor (72 percent) than with either losartan or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    (29 to 34 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=see_link\">",
"     \"Renin-angiotensin system inhibition in the treatment of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ACE inhibitor-induced cough has the following general features [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It usually begins within one week of instituting therapy, but the onset can be delayed up to six months.",
"     </li>",
"     <li>",
"      It often presents with a tickling, scratchy, or itchy sensation in the throat [",
"      <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It typically resolves within one to four days of discontinuing therapy, but can take up to four weeks.",
"     </li>",
"     <li>",
"      It generally recurs with rechallenge, either with the same or a different ACE inhibitor.",
"     </li>",
"     <li>",
"      It is a more common complication in women than in men, and is also more common in those of Chinese ancestry [",
"      <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It does not occur more frequently in asthmatics than in non-asthmatics.",
"     </li>",
"     <li>",
"      It is generally not accompanied by airflow obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/63\">",
"       63",
"      </a>",
"      ]. In one study, for every 10 patients with cough induced by ACE inhibitors, there was approximately one patient with development or aggravation of asthma, bronchospasm, or dyspnea [",
"      <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/64\">",
"       64",
"      </a>",
"      ]. Cough did not necessarily accompany these other respiratory problems.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment consists of discontinuing the ACE inhibitor and, if necessary, switching the patient to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    or another angiotensin II receptor antagonist [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chronic bronchitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic bronchitis is defined as the presence of cough and sputum production on most days over at least a three-month period for more than two consecutive years in a patient without other explanations for cough. Almost all patients are smokers, except a small number who have chronic exposure to and airway inflammation due to other fumes or dusts. Because of the high prevalence of smoking, chronic bronchitis remains one of the most frequent causes of chronic cough. However, most smokers with chronic bronchitis do not seek medical attention for their cough, and in most series of chronic cough, chronic bronchitis accounts for 5 percent or less of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sputum produced is usually clear or white. A purulent appearance to sputum often suggests a concomitant upper or lower respiratory infection, such as acute bronchitis, bronchiectasis, or sinusitis. In any smoker who presents for evaluation of cough, one must ensure that the symptoms do not represent a change in a chronic cough that is suggestive of a neoplasm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=see_link\">",
"     \"Management of infection in acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=see_link\">",
"     \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bronchiectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchiectasis results from severe, repeated, or persistent airway inflammation that leads to progressive airway damage. Bronchi become dilated and cystic, leading to poor mucus clearance, secretion pooling, and chronic infection of the lower respiratory tract. This, in turn, serves to worsen airway inflammation and bronchial destruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cough is a major symptom of bronchiectasis, and in some studies, bronchiectasis is the cause of chronic cough in 4 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/2,65\">",
"     2,65",
"    </a>",
"    ]. While some patients with bronchiectasis have only a dry cough, most produce chronic sputum that is mucopurulent, and which becomes frankly purulent during an exacerbation. The lung examination may be surprisingly normal, but more often reveals focal or bilateral rhonchi, crackles, or wheezes. The chest radiograph may suggest the disease by demonstrating crowded lung markings, thickened bronchial walls, or small fluid-filled cystic structures. However, these findings are insensitive and nonspecific, and chest CT with high resolution imaging is the optimal method of securing the diagnosis.",
"   </p>",
"   <p>",
"    Once bronchiectasis is diagnosed, one should attempt to define its cause. Focal bronchiectasis is often the result of a prolonged or severe remote lower respiratory infection. Multifocal bronchiectasis, especially in a middle aged woman, is often due to chronic lower airway infection with Mycobacterium avium complex (MAC). More diffuse bronchiectasis, especially in a younger individual, raises the possibility of cystic fibrosis or an immunoglobulin deficiency state.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchogenic carcinoma is a feared diagnosis in which cough is present in a significant number of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/66\">",
"     66",
"    </a>",
"    ]. However, lung cancer is the etiology in less than 2 percent of the cases of chronic cough [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/1,2,66\">",
"     1,2,66",
"    </a>",
"    ]. Most cases of lung cancer that manifest with cough are due to neoplasms originating in the large central airways, where cough receptors are common. Physical examination may reveal focal wheezing or diminished breath sounds, indicative of focal airway obstruction from tumor. Pulmonary lymphangitic carcinomatosis from extrapulmonary malignancies can also present as cough, but is generally accompanied by dyspnea.",
"   </p>",
"   <p>",
"    Bronchogenic cancer should be considered as a possible etiology of cough in any current or former smoker, and should be particularly suspected in those with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A new cough or a recent change in chronic \"smoker's cough\"",
"     </li>",
"     <li>",
"      A cough that persists more than one month following smoking cessation",
"     </li>",
"     <li>",
"      Hemoptysis that does not occur in the setting of an airway infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=see_link\">",
"     \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nonasthmatic eosinophilic bronchitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonasthmatic eosinophilic bronchitis is an increasingly recognized cause of chronic nonproductive cough, particularly in patients who lack any of the risk factors described above [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/67-71\">",
"     67-71",
"    </a>",
"    ]. Patients with this disorder demonstrate atopic tendencies, with elevated sputum eosinophils and active airway inflammation in the",
"    <strong>",
"     absence",
"    </strong>",
"    of airway hyperresponsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/67\">",
"     67",
"    </a>",
"    ]. These same findings",
"    <strong>",
"     with",
"    </strong>",
"    evidence of hyperresponsiveness are consistent with the diagnosis of cough-variant asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Asthma'",
"    </a>",
"    above.) In one series of 20 patients with chronic isolated (nonspecific) cough, no apparent cause, and no airway hyperresponsiveness, bronchial biopsy revealed eosinophilic bronchitis in 16 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although bronchial mucosal biopsies are required to definitively diagnose eosinophilic bronchitis, a trial of therapy is usually performed without biopsy, since most patients respond well to inhaled glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/69,72\">",
"     69,72",
"    </a>",
"    ]. Airway eosinophils and basement membrane thickening are present in both asthma and eosinophilic bronchitis, but mast cell infiltration is noted only in asthmatics, which may explain the differences in airway reactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/73-75\">",
"     73-75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history of nonasthmatic eosinophilic bronchitis is variable. One year follow-up of a cohort of 367 patients with normal lung function and eosinophilic inflammation noted that 55 percent remained symptomatic with normal lung function, 32 percent were free of symptoms, and 13 percent developed asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/76\">",
"     76",
"    </a>",
"    ]. Patients with recurrent episodes of symptomatic eosinophilic bronchitis appear to be at increased risk of asthma and chronic airway obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Rare causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the elderly or infirm, swallowing dysfunction may lead to recurrent aspiration and chronic cough. Formal assessment by a speech pathologist may be needed for clinically silent aspiration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=see_link&amp;anchor=H2#H2\">",
"     \"Aspiration pneumonia in adults\", section on 'Predisposing conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lesions that compress the upper airway, including arteriovenous malformations and retrotracheal masses, may present with chronic cough [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. Cough also can be a symptom of tracheobronchomalacia, which results from loss of rigid support of the large airways and inspiratory collapse, and is usually seen in conjunction with obstructive lung disease in patients with a history of cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/81\">",
"     81",
"    </a>",
"    ]. Tracheal diverticuli have also been noted in association with chronic cough [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25256?source=see_link\">",
"     \"Radiology of the trachea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laryngeal sensory neuropathy has been identified as the cause of chronic cough in 18 of 26 patients with acute onset of cough that was often associated with laryngospasm or throat clearing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/83\">",
"     83",
"    </a>",
"    ]. The diagnosis was made by laryngeal electromyography or videostroboscopy, usually after exclusion or treatment of other causes of chronic cough.",
"   </p>",
"   <p>",
"    Chronic tonsillar enlargement has been proposed as a cause of chronic cough, but clinical evidence of this association is limited. One series of 236 patients referred for evaluation in a specialized clinic noted tonsillar enlargement in the absence of other known causes of chronic cough in eight individuals (3.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/84\">",
"     84",
"    </a>",
"    ]. Following tonsillectomy, these patients had decreased cough sensitivity and significantly improved symptom control. These intriguing preliminary observations require further investigation before this approach can be recommended.",
"   </p>",
"   <p>",
"    Irritation of the external auditory canal by impacted foreign bodies or cerumen is another unusual cause of chronic dry cough [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/85\">",
"     85",
"    </a>",
"    ]. The etiology of the \"ear-cough\" (or oto-respiratory) reflex is related to stimulation of the auricular branch of the vagus nerve (Arnold's nerve) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. For this reason, otoscopic examination should be performed in patients with an undiagnosed chronic cough.",
"   </p>",
"   <p>",
"    Premature ventricular contractions (PVCs) may rarely cause a chronic cough. In a series of 120 patients referred to an electrophysiology center for evaluation of PVCs, six had a chronic cough that either disappeared upon spontaneous resolution of the PVCs or markedly improved with treatment of the arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another rare cause of chronic cough is Holmes-Adie syndrome due to autonomic dysfunction affecting the vagus nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44117?source=see_link\">",
"     \"Tonic pupil\"",
"    </a>",
"    .) Patients present with anisocoria, abnormal deep tendon reflexes, and patchy areas of hyperhidrosis or anhidrosis.",
"   </p>",
"   <p>",
"    In adults, habit (also known as \"psychogenic\") cough may rarely be the cause of a chronic cough that remains troublesome despite a thorough evaluation, including ruling out tic disorders (",
"    <a class=\"graphic graphic_algorithm graphicRef67147 \" href=\"UTD.htm?10/14/10465\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/90\">",
"     90",
"    </a>",
"    ]. No particular clinical manifestations or associated conditions have been confirmed, although patients should be evaluated for common problems such as anxiety, depression, and domestic violence. The diagnostic features are the lack of a diagnosis following a complete evaluation and improvement with behavior modification or psychiatric therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;During vigorous coughing, intrathoracic pressures may reach 300 mmHg and expiratory velocities approach 500 miles per hour [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/91\">",
"     91",
"    </a>",
"    ]. While these pressures and velocities are responsible for the beneficial effects of cough on mucus clearance, they are also responsible for many of the complications of cough, including exhaustion, self-consciousness, insomnia, headache, dizziness, musculoskeletal pain, hoarseness, excessive perspiration, urinary incontinence, and concern that \"something is wrong\" (",
"    <a class=\"graphic graphic_table graphicRef63151 \" href=\"UTD.htm?0/51/829\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/1,92\">",
"     1,92",
"    </a>",
"    ]. Cough-induced rib fractures are another painful and potentially serious complication of chronic cough. Fractures often involve multiple ribs, particularly ribs five through seven. Women with decreased bone density are at the greatest risk of this complication; however, fractures can occur in patients with normal bone density as well [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history often provides important initial clues in the patient with subacute or chronic cough. All patients should be questioned about the use of ACE inhibitors and about the presence of an upper respiratory tract infection at the onset of the cough [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/94\">",
"     94",
"    </a>",
"    ]. A history of coexisting symptoms might suggest an underlying diagnosis (eg, asthma, postnasal drip, gastroesophageal reflux, chronic bronchitis, bronchiectasis). Somewhat surprisingly, one study found that the character and timing of the cough and the presence or absence of sputum production do not appear to aid in the differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/17\">",
"     17",
"    </a>",
"    ]. In patients whose cough has lasted more than eight weeks, a chest radiograph should be considered as part of the initial evaluation, especially if upper airway cough syndrome, asthma, or gastroesophageal reflux are not considered clinically likely [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Upper airway cough syndrome, asthma, and gastroesophageal reflux, alone or in combination, are responsible for approximately 90 percent of cases of chronic cough [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/2,3,16,17\">",
"     2,3,16,17",
"    </a>",
"    ]. However, one study found that these disorders were responsible for 99.4 percent of patients who had the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nonsmoker",
"     </li>",
"     <li>",
"      No use of an ACE inhibitor",
"     </li>",
"     <li>",
"      Normal or near normal and stable plain chest radiograph",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     Methacholine",
"    </a>",
"    challenge and esophageal pH monitoring are useful diagnostic studies in the evaluation of selected patients with chronic cough [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]. Using an approach that stresses the importance of these studies, one report was able to document an etiology for chronic cough in 99 percent of patients, and specific therapy was reported to be successful in 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/2\">",
"     2",
"    </a>",
"    ]. Another study stressed the high frequency of postnasal drip contributing to cough and suggested initial empiric therapy with an antihistamine-decongestant combination [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/16\">",
"     16",
"    </a>",
"    ]. In this report, the antihistamine-decongestant was the only therapy needed in 16 of 45 patients (36 percent), while an additional 23 patients had at least some benefit.",
"   </p>",
"   <p>",
"    If empiric treatment of postnasal drip is unsuccessful, a stepwise approach should be initiated that emphasizes sequential diagnostic testing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    empiric therapy for asthma, non-asthmatic eosinophilic bronchitis, and gastroesophageal reflux disease (",
"    <a class=\"graphic graphic_algorithm graphicRef67147 \" href=\"UTD.htm?10/14/10465\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/1\">",
"     1",
"    </a>",
"    ]. In general, flexible fiberoptic bronchoscopy adds little to the diagnostic evaluation of patients with normal or nonspecific findings on plain chest radiographs or thoracic CT [",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/95\">",
"     95",
"    </a>",
"    ]. However, fiberoptic bronchoscopy may rarely identify an unsuspected foreign body.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=see_link\">",
"       \"Patient information: Cough in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/11/4275?source=see_link\">",
"       \"Patient information: Asthma in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/34/28195?source=see_link\">",
"       \"Patient information: Chronic cough in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on findings primarily from cohort and case control studies, and synthesized by experts in the field, we recommend the stepwise approach shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef67147 \" href=\"UTD.htm?10/14/10465\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/18/5418/abstract/1\">",
"     1",
"    </a>",
"    ]. This approach emphasizes empirical therapy and relatively simple diagnostic evaluation if the initial basic evaluation does not provide clues to possible etiology. More detailed diagnostic evaluation can be reserved for those patients whose diagnosis remains unclear and in whom empiric therapy does not successfully treat the cough.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial evaluation including history and physical examination should be performed, with particular attention paid to the possibility of a postinfectious etiology. If the patient has been on an ACE inhibitor, the medication should be discontinued. Therapy aimed at a particular etiology should be given based on clues from the initial evaluation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In adult patients whose cough has lasted more than eight weeks, a chest radiograph is typically performed as part of the initial evaluation, to rule out a potential etiology that would require additional evaluation or focused treatment. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnostic approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Lung cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If no clues are provided by the initial evaluation, the first step in the majority of patients is to start empiric therapy for postnasal drip with a first generation antihistamine-decongestant combination (",
"      <a class=\"graphic graphic_algorithm graphicRef67147 \" href=\"UTD.htm?10/14/10465\">",
"       algorithm 1",
"      </a>",
"      ). If the patient obtains complete relief with this empiric regimen and can be weaned off of the antihistamine-decongestant regimen, then no further evaluation is needed. If postnasal drip is felt likely to be allergic in origin, testing for sensitivity to specific allergens in the home or work environment may be helpful, or the patient can be tried on more specific treatment for allergic rhinitis. If the patient has only partial relief from a first generation antihistamine-decongestant combination or has side effects from the antihistamine-decongestant combination, then addition of topical therapy with a nasal glucocorticoid, a nasal anticholinergic agent, or a nasal antihistamine may provide additional improvement. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Upper airway cough syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27913?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of subacute and chronic cough in adults\", section on 'Upper airway cough syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link\">",
"       \"An overview of rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If there is no improvement after two to three weeks of empiric therapy for postnasal drip, then pre- and post-bronchodilator spirometry should be performed. If this testing does not suggest reversible airflow obstruction, then a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      challenge study is typically performed to identify bronchial hyperresponsiveness. Treatment with inhaled bronchodilator",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inhaled glucocorticoids is initiated if there is baseline airflow obstruction or if the methacholine challenge is positive. An alternative approach is empiric therapy for asthma rather than extensive diagnostic testing, using the response to such therapy as both a diagnostic and therapeutic trial. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Asthma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27913?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment of subacute and chronic cough in adults\", section on 'Cough variant asthma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the above studies are negative, then the patient should be evaluated (through demonstration of sputum eosinophilia) or simply treated empirically (with inhaled glucocorticoids) for nonasthmatic eosinophilic bronchitis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Nonasthmatic eosinophilic bronchitis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27913?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of subacute and chronic cough in adults\", section on 'Nonasthmatic eosinophilic bronchitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the cough remains problematic, the patient should be treated empirically for gastroesophageal reflux with a proton pump inhibitor and with appropriate lifestyle and dietary modifications. If the patient has an incomplete response to therapy for gastroesophageal reflux, additional diagnostic studies may be warranted before concluding that gastroesophageal reflux is not contributing. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Gastroesophageal reflux'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27913?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of subacute and chronic cough in adults\", section on 'Gastroesophageal reflux'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rare causes of cough are evaluated based on the clinical setting and absence of response to the above therapies (",
"      <a class=\"graphic graphic_table graphicRef57282 \" href=\"UTD.htm?17/58/18347\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Rare causes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At present, conclusive data regarding the cost effectiveness and long-term outcome of this, or any, strategy of evaluation and treatment are lacking. More detailed discussion of specific therapy for the causes of chronic cough as well as nonspecific suppressive therapy of cough is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27913?source=see_link\">",
"     \"Treatment of subacute and chronic cough in adults\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/1\">",
"      Irwin RS, Baumann MH, Bolser DC, et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/2\">",
"      Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis 1990; 141:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/3\">",
"      Irwin RS, Corrao WM, Pratter MR. Chronic persistent cough in the adult: the spectrum and frequency of causes and successful outcome of specific therapy. Am Rev Respir Dis 1981; 123:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/4\">",
"      Kelsall A, Decalmer S, McGuinness K, et al. Sex differences and predictors of objective cough frequency in chronic cough. Thorax 2009; 64:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/5\">",
"      Haque RA, Usmani OS, Barnes PJ. Chronic idiopathic cough: a discrete clinical entity? Chest 2005; 127:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/6\">",
"      Morice AH, Geppetti P. Cough. 5: The type 1 vanilloid receptor: a sensory receptor for cough. Thorax 2004; 59:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/7\">",
"      Trevisani M, Milan A, Gatti R, et al. Antitussive activity of iodo-resiniferatoxin in guinea pigs. Thorax 2004; 59:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/8\">",
"      Groneberg DA, Niimi A, Dinh QT, et al. Increased expression of transient receptor potential vanilloid-1 in airway nerves of chronic cough. Am J Respir Crit Care Med 2004; 170:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/9\">",
"      Birrell MA, Belvisi MG, Grace M, et al. TRPA1 agonists evoke coughing in guinea pig and human volunteers. Am J Respir Crit Care Med 2009; 180:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/10\">",
"      Belvisi MG, Dubuis E, Birrell MA. Transient receptor potential A1 channels: insights into cough and airway inflammatory disease. Chest 2011; 140:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/11\">",
"      Morice A, Kastelik JA, Thompson RH. Gender differences in airway behaviour. Thorax 2000; 55:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/12\">",
"      Kastelik JA, Thompson RH, Aziz I, et al. Sex-related differences in cough reflex sensitivity in patients with chronic cough. Am J Respir Crit Care Med 2002; 166:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/13\">",
"      Morice AH, Kastelik JA. Cough. 1: Chronic cough in adults. Thorax 2003; 58:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/14\">",
"      Kastelik JA, Aziz I, Ojoo JC, et al. Investigation and management of chronic cough using a probability-based algorithm. Eur Respir J 2005; 25:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/15\">",
"      Irwin RS, Madison JM. The diagnosis and treatment of cough. N Engl J Med 2000; 343:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/16\">",
"      Pratter MR, Bartter T, Akers S, DuBois J. An algorithmic approach to chronic cough. Ann Intern Med 1993; 119:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/17\">",
"      Mello CJ, Irwin RS, Curley FJ. Predictive values of the character, timing, and complications of chronic cough in diagnosing its cause. Arch Intern Med 1996; 156:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/18\">",
"      McGarvey LP, Heaney LG, Lawson JT, et al. Evaluation and outcome of patients with chronic non-productive cough using a comprehensive diagnostic protocol. Thorax 1998; 53:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/19\">",
"      Kwon NH, Oh MJ, Min TH, et al. Causes and clinical features of subacute cough. Chest 2006; 129:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/20\">",
"      Birring SS. Controversies in the evaluation and management of chronic cough. Am J Respir Crit Care Med 2011; 183:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/21\">",
"      Patrick H, Patrick F. Chronic cough. Med Clin North Am 1995; 79:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/22\">",
"      Pratter MR, Bartter T, Lotano R. The role of sinus imaging in the treatment of chronic cough in adults. Chest 1999; 116:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/23\">",
"      Holinger LD, Sanders AD. Chronic cough in infants and children: an update. Laryngoscope 1991; 101:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/24\">",
"      Corrao WM, Braman SS, Irwin RS. Chronic cough as the sole presenting manifestation of bronchial asthma. N Engl J Med 1979; 300:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/25\">",
"      Johnson D, Osborn LM. Cough variant asthma: a review of the clinical literature. J Asthma 1991; 28:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/26\">",
"      O'Connell EJ, Rojas AR, Sachs MI. Cough-type asthma: a review. Ann Allergy 1991; 66:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/27\">",
"      Nakajima T, Nishimura Y, Nishiuma T, et al. Characteristics of patients with chronic cough who developed classic asthma during the course of cough variant asthma: a longitudinal study. Respiration 2005; 72:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/28\">",
"      McFadden ER Jr. Exertional dyspnea and cough as preludes to acute attacks of bronchial asthma. N Engl J Med 1975; 292:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/29\">",
"      Niimi A, Matsumoto H, Mishima M. Eosinophilic airway disorders associated with chronic cough. Pulm Pharmacol Ther 2009; 22:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/30\">",
"      Oh MJ, Lee JY, Lee BJ, Choi DC. Exhaled nitric oxide measurement is useful for the exclusion of nonasthmatic eosinophilic bronchitis in patients with chronic cough. Chest 2008; 134:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/31\">",
"      Hahn PY, Morgenthaler TY, Lim KG. Use of exhaled nitric oxide in predicting response to inhaled corticosteroids for chronic cough. Mayo Clin Proc 2007; 82:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/32\">",
"      Prieto L, Ferrer A, Ponce S, et al. Exhaled nitric oxide measurement is not useful for predicting the response to inhaled corticosteroids in subjects with chronic cough. Chest 2009; 136:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/33\">",
"      Poe RH, Kallay MC. Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment. Chest 2003; 123:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/34\">",
"      Irwin RS, Zawacki JK, Curley FJ, et al. Chronic cough as the sole presenting manifestation of gastroesophageal reflux. Am Rev Respir Dis 1989; 140:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/35\">",
"      Irwin RS, French CL, Curley FJ, et al. Chronic cough due to gastroesophageal reflux. Clinical, diagnostic, and pathogenetic aspects. Chest 1993; 104:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/36\">",
"      Fontana GA, Pistolesi M. Cough. 3: chronic cough and gastro-oesophageal reflux. Thorax 2003; 58:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/37\">",
"      Irwin RS, Richter JE. Gastroesophageal reflux and chronic cough. Am J Gastroenterol 2000; 95:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/38\">",
"      Ing AJ, Ngu MC, Breslin AB. Pathogenesis of chronic persistent cough associated with gastroesophageal reflux. Am J Respir Crit Care Med 1994; 149:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/39\">",
"      Patterson RN, Johnston BT, MacMahon J, et al. Oesophageal pH monitoring is of limited value in the diagnosis of \"reflux-cough\". Eur Respir J 2004; 24:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/40\">",
"      Kastelik JA, Redington AE, Aziz I, et al. Abnormal oesophageal motility in patients with chronic cough. Thorax 2003; 58:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/41\">",
"      Fouad YM, Katz PO, Hatlebakk JG, Castell DO. Ineffective esophageal motility: the most common motility abnormality in patients with GERD-associated respiratory symptoms. Am J Gastroenterol 1999; 94:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/42\">",
"      Knight RE, Wells JR, Parrish RS. Esophageal dysmotility as an important co-factor in extraesophageal manifestations of gastroesophageal reflux. Laryngoscope 2000; 110:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/43\">",
"      Koufman JA, Aviv JE, Casiano RR, Shaw GY. Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg 2002; 127:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/44\">",
"      Poe RH, Harder RV, Israel RH, Kallay MC. Chronic persistent cough. Experience in diagnosis and outcome using an anatomic diagnostic protocol. Chest 1989; 95:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/45\">",
"      Davis SF, Sutter RW, Strebel PM, et al. Concurrent outbreaks of pertussis and Mycoplasma pneumoniae infection: clinical and epidemiological characteristics of illnesses manifested by cough. Clin Infect Dis 1995; 20:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/46\">",
"      Yaari E, Yafe-Zimerman Y, Schwartz SB, et al. Clinical manifestations of Bordetella pertussis infection in immunized children and young adults. Chest 1999; 115:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/47\">",
"      Curley FJ, Irwin RS, Pratter MR, et al. Cough and the common cold. Am Rev Respir Dis 1988; 138:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/48\">",
"      O'Connell F, Thomas VE, Pride NB, Fuller RW. Capsaicin cough sensitivity decreases with successful treatment of chronic cough. Am J Respir Crit Care Med 1994; 150:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/49\">",
"      Hegele RG, Hayashi S, Hogg JC, Par&eacute; PD. Mechanisms of airway narrowing and hyperresponsiveness in viral respiratory tract infections. Am J Respir Crit Care Med 1995; 151:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/50\">",
"      Folkerts G, Nijkamp FP. Virus-induced airway hyperresponsiveness. Role of inflammatory cells and mediators. Am J Respir Crit Care Med 1995; 151:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/51\">",
"      Dworkin MS. Adults are whooping, but are internists listening? Ann Intern Med 2005; 142:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/52\">",
"      G&uuml;ri D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999; 28:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/53\">",
"      Strebel P, Nordin J, Edwards K, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. J Infect Dis 2001; 183:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/54\">",
"      Wright SW, Edwards KM, Decker MD, Zeldin MH. Pertussis infection in adults with persistent cough. JAMA 1995; 273:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/55\">",
"      Cherry JD. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin Infect Dis 1999; 28 Suppl 2:S112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/56\">",
"      Hewlett EL, Edwards KM. Clinical practice. Pertussis--not just for kids. N Engl J Med 2005; 352:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/57\">",
"      Schaefer OP, Irwin RS. Unsuspected bacterial suppurative disease of the airways presenting as chronic cough. Am J Med 2003; 114:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/58\">",
"      Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/59\">",
"      Dykewicz MS. Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management. Curr Opin Allergy Clin Immunol 2004; 4:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/60\">",
"      Lacourci&egrave;re Y, Lefebvre J, Nakhle G, et al. Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study. J Hypertens Suppl 1994; 12:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/61\">",
"      Lacourci&egrave;re Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group. J Hypertens 1994; 12:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/62\">",
"      Tseng DS, Kwong J, Rezvani F, Coates AO. Angiotensin-converting enzyme-related cough among Chinese-Americans. Am J Med 2010; 123:183.e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/63\">",
"      Boulet LP, Milot J, Lampron N, Lacourci&egrave;re Y. Pulmonary function and airway responsiveness during long-term therapy with captopril. JAMA 1989; 261:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/64\">",
"      Lunde H, Hedner T, Samuelsson O, et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1994; 308:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/65\">",
"      Smyrnios NA, Irwin RS, Curley FJ. Chronic cough with a history of excessive sputum production. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Chest 1995; 108:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/66\">",
"      Hyde L, Hyde CI. Clinical manifestations of lung cancer. Chest 1974; 65:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/67\">",
"      Brightling CE, Ward R, Woltmann G, et al. Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. Am J Respir Crit Care Med 2000; 162:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/68\">",
"      Lee SY, Cho JY, Shim JJ, et al. Airway inflammation as an assessment of chronic nonproductive cough. Chest 2001; 120:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/69\">",
"      Brightling CE, Pavord ID. Eosinophilic bronchitis: an important cause of prolonged cough. Ann Med 2000; 32:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/70\">",
"      Fujimura M. Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med 2000; 161:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/71\">",
"      Fujimura M, Ogawa H, Yasui M, Matsuda T. Eosinophilic tracheobronchitis and airway cough hypersensitivity in chronic non-productive cough. Clin Exp Allergy 2000; 30:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/72\">",
"      Gibson PG, Fujimura M, Niimi A. Eosinophilic bronchitis: clinical manifestations and implications for treatment. Thorax 2002; 57:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/73\">",
"      Brightling CE, Bradding P, Symon FA, et al. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/74\">",
"      Brightling CE, Symon FA, Birring SS, et al. Comparison of airway immunopathology of eosinophilic bronchitis and asthma. Thorax 2003; 58:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/75\">",
"      Kanazawa H, Nomura S, Yoshikawa J. Role of microvascular permeability on physiologic differences in asthma and eosinophilic bronchitis. Am J Respir Crit Care Med 2004; 169:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/76\">",
"      Rytil&auml; P, Metso T, Heikkinen K, et al. Airway inflammation in patients with symptoms suggesting asthma but with normal lung function. Eur Respir J 2000; 16:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/77\">",
"      Park SW, Lee YM, Jang AS, et al. Development of chronic airway obstruction in patients with eosinophilic bronchitis: a prospective follow-up study. Chest 2004; 125:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/78\">",
"      McLaughlin RB Jr, Wetmore RF, Tavill MA, et al. Vascular anomalies causing symptomatic tracheobronchial compression. Laryngoscope 1999; 109:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/79\">",
"      G&uuml;lmez I, Ouzkaya F, Bilgin M, et al. Posterior mediastinal goiter. Monaldi Arch Chest Dis 1999; 54:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/80\">",
"      Waldron D, Coffey J, Murphy S, et al. Retrotracheal goiter: a diagnostic and therapeutic problem. Ann Thorac Surg 1990; 50:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/81\">",
"      Thornton M, Rowley H, Cummiskey J, Timon C. Chronic cough: an unusual cause, an unusual cure. Arch Otolaryngol Head Neck Surg 2001; 127:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/82\">",
"      Infante M, Mattavelli F, Valente M, et al. Tracheal diverticulum: a rare cause and consequence of chronic cough. Eur J Surg 1994; 160:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/83\">",
"      Lee B, Woo P. Chronic cough as a sign of laryngeal sensory neuropathy: diagnosis and treatment. Ann Otol Rhinol Laryngol 2005; 114:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/84\">",
"      Birring SS, Passant C, Patel RB, et al. Chronic tonsillar enlargement and cough: preliminary evidence of a novel and treatable cause of chronic cough. Eur Respir J 2004; 23:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/85\">",
"      Jegoux F, Legent F, Beauvillain de Montreuil C. Chronic cough and ear wax. Lancet 2002; 360:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/86\">",
"      Bloustine S, Langston L, Miller T. Ear-cough (Arnold's) reflex. Ann Otol Rhinol Laryngol 1976; 85:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/87\">",
"      Feldman JI, Woodworth WF. Cause for intractable chronic cough: Arnold's nerve. Arch Otolaryngol Head Neck Surg 1993; 119:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/88\">",
"      Stec SM, Grabczak EM, Bielicki P, et al. Diagnosis and management of premature ventricular complexes-associated chronic cough. Chest 2009; 135:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/89\">",
"      Ford PA, Barnes PJ, Usmani OS. Chronic cough and Holmes-Adie syndrome. Lancet 2007; 369:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/90\">",
"      Irwin RS, Glomb WB, Chang AB. Habit cough, tic cough, and psychogenic cough in adult and pediatric populations: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:174S.",
"     </a>",
"    </li>",
"    <li>",
"     Comroe JH Jr. Special acts involving breathing. In: Physiology of Respiration: An Introductory Text, 2nd ed, Year Book Medical Publishers, Chicago 1974. p.230.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/92\">",
"      Smyrnios NA, Irwin RS, Curley FJ, French CL. From a prospective study of chronic cough: diagnostic and therapeutic aspects in older adults. Arch Intern Med 1998; 158:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/93\">",
"      Hanak V, Hartman TE, Ryu JH. Cough-induced rib fractures. Mayo Clin Proc 2005; 80:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/94\">",
"      Morice AH, Fontana GA, Sovijarvi AR, et al. The diagnosis and management of chronic cough. Eur Respir J 2004; 24:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/18/5418/abstract/95\">",
"      Barnes TW, Afessa B, Swanson KL, Lim KG. The clinical utility of flexible bronchoscopy in the evaluation of chronic cough. Chest 2004; 126:268.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1460 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_18_5418=[""].join("\n");
var outline_f5_18_5418=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COUGH REFLEX ARC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Upper airway cough syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gastroesophageal reflux",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Laryngopharyngeal reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Respiratory tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chronic bronchitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bronchiectasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nonasthmatic eosinophilic bronchitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Rare causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1460\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1460|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?10/14/10465\" title=\"algorithm 1\">",
"      Algorithm for cough evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1460|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/15/34046\" title=\"figure 1\">",
"      Mechanisms cough reflex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1460|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/58/18347\" title=\"table 1\">",
"      Less common causes of cough",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/51/829\" title=\"table 2\">",
"      Complications of cough",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29289?source=related_link\">",
"      Acute bronchitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=related_link\">",
"      An overview of rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=related_link\">",
"      Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39816?source=related_link\">",
"      Gastroesophageal reflux and asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33960?source=related_link\">",
"      Laryngopharyngeal reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7866?source=related_link\">",
"      Management of infection in acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10186?source=related_link\">",
"      Neuronal control of the airways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=related_link\">",
"      Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/11/4275?source=related_link\">",
"      Patient information: Asthma in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/34/28195?source=related_link\">",
"      Patient information: Chronic cough in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=related_link\">",
"      Patient information: Cough in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25256?source=related_link\">",
"      Radiology of the trachea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=related_link\">",
"      Renin-angiotensin system inhibition in the treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44117?source=related_link\">",
"      Tonic pupil",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27913?source=related_link\">",
"      Treatment of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_18_5419="Causes of a dry tap";
var content_f5_18_5419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F72363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F72363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of a dry tap",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cause",
"       </td>",
"       <td class=\"subtitle1\">",
"        Setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obesity",
"       </td>",
"       <td>",
"        Particularly likely when leg is large and suspected effusion is small",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thick medial trianglular fat or medial plica",
"       </td>",
"       <td>",
"        Likely when lateral approach is successful after medial approach fails",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lipoma arborescens or gelatinous \"pseudoeffusion\"",
"       </td>",
"       <td>",
"        Likely in particularly large and chronic inflammatory effusions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obstruction of needle lumen by particular matter",
"       </td>",
"       <td>",
"        Likely in rheumatoid effusion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_18_5419=[""].join("\n");
var outline_f5_18_5419=null;
var title_f5_18_5420="Positive cultures in miliary TB";
var content_f5_18_5420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of positive smear or culture in patients with miliary tuberculosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Site",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maartens, 1990",
"       </td>",
"       <td class=\"subtitle1\">",
"        Kim, 1990",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sputum smear",
"       </td>",
"       <td>",
"        33*",
"       </td>",
"       <td>",
"        36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sputum culture",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BAL smear",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BAL culture",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric aspirate smear",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric aspirate culture",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine smear",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine culture",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CSF smear",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CSF culture",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serosal smear",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serosal culture",
"       </td>",
"       <td>",
"        44&bull;",
"       </td>",
"       <td>",
"        14&Delta;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All numbers are percentages.",
"     <br>",
"      &bull; 9 ascites, 7 pleural, 2 pericardial.",
"      <br>",
"       &Delta; All pleural.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_18_5420=[""].join("\n");
var outline_f5_18_5420=null;
var title_f5_18_5421="Ovarian failure anticancer Rx";
var content_f5_18_5421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chemotherapy-associated ovarian toxicity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class (action)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Definitely associated with ovarian damage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nitrogen mustard",
"       </td>",
"       <td>",
"        Mechlorethamine (alkylating agent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        L-phenylalanine mustard",
"       </td>",
"       <td>",
"        Mechlorethamine (alkylating agent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chlorambucil",
"       </td>",
"       <td>",
"        Chloroethylamine (alkylating agent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        Chloroethylamine (alkylating agent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Melphalan",
"       </td>",
"       <td>",
"        Mechlorethamine (alkylating agent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Busulfan",
"       </td>",
"       <td>",
"        Alkylalkane sulfonate (alkylating agent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Procarbazine",
"       </td>",
"       <td>",
"        Substituted hydrazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dacarbazine",
"       </td>",
"       <td>",
"        Alkylating agent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Probably associated with ovarian damage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vinblastine",
"       </td>",
"       <td>",
"        Vinca alkaloid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytosine arabinoside (Ara-C)",
"       </td>",
"       <td>",
"        Antimetabolite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cis-platinum",
"       </td>",
"       <td>",
"        Heavy metal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carmustine",
"       </td>",
"       <td>",
"        Nitrosourea (alkylating agent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lomustine",
"       </td>",
"       <td>",
"        Nitrosourea (alkylating agent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        VP-16 (etoposide)",
"       </td>",
"       <td>",
"        Podophyllotoxin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Imatinib",
"       </td>",
"       <td>",
"        Tyrosine kinase inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Low probability of ovarian damage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methotrexate",
"       </td>",
"       <td>",
"        Antimetabolite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluorouracil (5-FU)",
"       </td>",
"       <td>",
"        Antimetabolite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6-mercaptopurine",
"       </td>",
"       <td>",
"        Antimetabolite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vincristine",
"       </td>",
"       <td>",
"        Vinca alkaloid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mitomycin",
"       </td>",
"       <td>",
"        Antibiotic (alkylating agent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        VM-26",
"       </td>",
"       <td>",
"        Podophyllotoxin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Daunorubicin",
"       </td>",
"       <td>",
"        Anthracycline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bleomycin",
"       </td>",
"       <td>",
"        Peptide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vindesine",
"       </td>",
"       <td>",
"        Vinca alkaloid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxorubicin",
"       </td>",
"       <td>",
"        Anthracyclin",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_18_5421=[""].join("\n");
var outline_f5_18_5421=null;
var title_f5_18_5422="AASLD ascites guideline";
var content_f5_18_5422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American Association for the Study of Liver Diseases (AASLD) recommendations for the management of adult patients with ascites due to cirrhosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Evaluation and diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal paracentesis should be performed and ascitic fluid should be obtained from inpatients and outpatients with clinically apparent new-onset ascites.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Because bleeding is sufficiently uncommon, the routine prophylactic use of fresh frozen plasma or platelets before paracentesis is not recommended.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Differential diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The initial laboratory investigation of ascitic fluid should include an ascitic fluid cell count and differential, ascitic fluid total protein, and serum-ascites albumin gradient (SAAG).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If ascitic fluid infection is suspected, ascitic fluid should be cultured at the bedside in blood culture bottles prior to initiation of antibiotics.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other studies of ascitic fluid can be ordered based on pretest probability of disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Testing serum for CA125 is not helpful in the differential diagnosis of ascites. Its use is not recommended in patients with ascites of any type.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Treatment of ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with ascites who are thought to have an alcohol component to their liver injury should abstain from alcohol consumption.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Firstline treatment of patients with cirrhosis and ascites consists of sodium restriction (88 mmol/day [2000 mg/day]) and diuretics (oral spironolactone with or without oral furosemide).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluid restriction is not necessary unless serum sodium is less than 120 to 125 mmol/L.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        An initial therapeutic abdominal paracentesis should be performed in patients with tense ascites. Sodium restriction and oral diuretics should then be initiated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diuretic-sensitive patients should preferably be treated with sodium restriction and oral diuretics rather than with serial paracenteses.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver transplantation should be considered in patients with cirrhosis and ascites.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Refractory ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serial therapeutic paracenteses are a treatment option for patients with refractory ascites.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postparacentesis albumin infusion may not be necessary for a single paracentesis of less than 4 to 5 L.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For large-volume paracenteses, an albumin infusion of 6 to 8 g/L of fluid removed can be considered.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Referral for liver transplantation should be expedited in patients with refractory ascites.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transjugular intrahepatic portasystemic stent-shunt (TIPS) may be considered in appropriately selected patients who meet criteria similar to those of published randomized trials.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peritoneovenous shunt, performed by a surgeon experienced with this technique, should be considered for patients with refractory ascites who are not candidates for paracenteses, transplant, or TIPS.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Hepatorenal syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Albumin infusion plus administration of vasoactive drugs such as octreotide and midodrine should be considered in the treatment of type I hepatorenal syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with cirrhosis, ascites, and type I hepatorenal syndrome should have an expedited referral for liver transplantation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Spontaneous bacterial peritonitis (SBP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with ascites admitted to the hospital should undergo abdominal paracentesis. Paracentesis should be repeated in patients (whether in the hospital or not) who develop signs or symptoms or laboratory abnormalities suggestive of infection (eg, abdominal pain or tenderness, fever, encephalopathy, renal failure, acidosis, or peripheral leukocytosis).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with ascitic fluid PMN counts &ge;250 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        (0.25 X 10",
"        <sup>",
"         9",
"        </sup>",
"        /L) should receive empiric antibiotic therapy, eg, an intravenous third-generation cephalosporin, preferably cefotaxime 2 g every 8 hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral ofloxacin (400 mg twice per day) can be considered a substitute for intravenous cefotaxime in inpatients without prior exposure to quinolones, vomiting, shock, grade II (or higher) hepatic encephalopathy, or serum creatinine &gt;3 mg/dL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with ascitic fluid polymorphonuclear leukocyte (PMN) counts &lt;250 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        (0.25 X 10",
"        <sup>",
"         9",
"        </sup>",
"        /L) and signs or symptoms of infection (temperature &gt;100&deg;F or abdominal pain or tenderness) should also receive empiric antibiotic therapy, eg, intravenous cefotaxime 2 g every 8 hours, while awaiting results of cultures.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        When the ascitic fluid of a patient with cirrhosis is found to have a PMN count &ge;250 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        (0.25 X 10",
"        <sup>",
"         9",
"        </sup>",
"        /L) and there is high suspicion of secondary peritonitis, it should also be tested for total protein, LDH, glucose, Gram stain, carcinoembryonic antigen, and alkaline phosphatase to assist with the distinction of SBP from secondary peritonitis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with ascitic fluid PMN counts &ge;250 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        (0.25 X 10",
"        <sup>",
"         9",
"        </sup>",
"        /L) and clinical suspicion of SBP, who also have a serum creatinine &gt;1 mg/dL, blood urea nitrogen &gt;30 mg/dL, or total bilirubin &gt;4 mg/dL should receive 1.5 g albumin/kg body weight within 6 hours of detection and 1.0 g/kg on day 3.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Prevention of spontaneous bacterial peritonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravenous ceftriaxone for 7 days or twice-daily norfloxacin for 7 days should be given to prevent bacterial infections in patients with cirrhosis and gastrointestinal hemorrhage.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients who have survived an episode of SBP should receive long-term prophylaxis with daily norfloxacin (or trimethoprim/sulfamethoxazole) because this is the most data-supported indication for long-term outpatient prophylaxis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In patients with cirrhosis and ascites but no gastrointestinal bleeding, long-term use of norfloxacin (or trimethoprim/sulfamethasoxazole) can be justified if the ascitic fluid protein &lt;1.5 g/dL and at least one of the following is present: serum creatinine &ge;1.2 mg/dL, blood urea nitrogen &ge;25 mg/dL, serum sodium &le;130 mEq/L, or Child-Pugh &ge;9 points with bilirubin &ge;3 mg/dL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intermittent dosing of antibiotics to prevent bacterial infections may be inferior to daily dosing (due to the development of bacterial resistance) and thus daily dosing should preferentially be used.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49:2087.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_18_5422=[""].join("\n");
var outline_f5_18_5422=null;
var title_f5_18_5423="ACC AHA ETT diagnosis CHD";
var content_f5_18_5423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74054%7ECARD%2F52995%7ECARD%2F61603%7ECARD%2F77242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74054%7ECARD%2F52995%7ECARD%2F61603%7ECARD%2F77242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Exercise ECG testing without an imaging modality for the diagnosis of obstructive coronary heart disease (CHD)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that exercise ECG testing for the diagnosis of CHD is indicated in patients with:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; An intermediate pretest probability of CHD based upon age, gender, and symptoms, including patients with complete right bundle branch block or less than 1 mm ST depression, in the absence of the exceptions listed in class IIb and class III.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of exercise ECG testing for the diagnosis of CHD in patients with:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Suspected variant (vasospastic) angina.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The usefulness of exercise ECG testing for the diagnosis of CHD is less well established in patients with:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; A high or low pretest probability of CHD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Digoxin therapy and less then 1 mm of ST segment depression at baseline.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Electrocardiographic evidence of left ventricular hypertrophy and and less then 1 mm of ST segment depression at baseline.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that exercise testing for risk assessment and prognosis in patients at intermediate or high probability of CHD is not useful in the following settings:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; Patients with the following baseline ECG abnormalities:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Preexcitation (Wolff-Parkinson-White) syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Electronically paced ventricular rhythm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. More than 1 mm of ST segment depression at rest.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Complete left bundle branch block.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; An established diagnosis of CHD due to prior myocardial infarction or coronary angiography. However, testing may be warranted in such patients to assess functional capacity and prognosis.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for cardiac stress imaging as the initial test for diagnosis of coronary heart disease (CHD) in patients with chronic stable angina who are able to exercise",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class I",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       1. Exercise myocardial perfusion imaging or exercise echocardiography in patients with an intermediate pretest probability of CAD who have one of the following baseline ECG abnormalities:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Pre-excitation (Wolff-Parkinson-White) syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. More than 1 mm of ST depression at rest",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2. Exercise myocardial perfusion imaging or exercise echocardiography in patients with prior revascularization (either PTCA or CABG).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       3. Adenosine or dipyridamole myocardial perfusion imaging in patients with an intermediate pretest probability of CAD and one of the following baseline ECG abnormalities:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Electronically paced ventricular rhythm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. Left bundle-branch block",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       4. Dobutamine stress echocardiography in patients with an intermediate pretest probability of CAD and left bundle branch block.*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class IIb",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       1. Exercise myocardial perfusion imaging and exercise echocardiography in patients with a low or high probability of CAD who have one of the following baseline ECG abnormalities:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Pre-excitation (Wolff-Parkinson-White) syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. More than 1 mm of ST depression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       2. Adenosine or dipyridamole myocardial perfusion imaging in patients with a low or high probability of CAD and one of the following baseline ECG abnormalities:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Electronically paced ventricular rhythm b. Left bundle-branch block",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       3. Exercise myocardial perfusion imaging or exercise echocardiography in patients with an intermediate probability of CAD who have one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Digoxin use with &lt;1 mm ST depression on the baseline ECG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. LVH with &lt;1 mm ST depression on the baseline ECG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       4. Exercise myocardial perfusion imaging, exercise echocardiography, adenosine or dipyridamole myocardial perfusion imaging or dobutamine echocardiography as the initial stress test in a patient with a normal rest ECG who is not taking digoxin.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       5. Exercise in patients with left bundle-branch block.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       ACC/AHA classification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class I:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       <strong>",
"        Class II:",
"       </strong>",
"       Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIa:",
"       </strong>",
"       Weight of evidence/opinion is in favor of usefulness/efficacy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIb:",
"       </strong>",
"       Usefulness/efficacy less well established by evidence/opinion.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class III:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Modified from: Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116:e418.",
"    </div>",
"    <div class=\"reference\">",
"     Data modified from: Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for cardiac stress imaging as the initial test for diagnosis of coronary heart disease (CHD) in patients with chronic stable angina who are unable to exercise",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class I",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1. Adenosine or dipyridamole myocardial perfusion imaging or dobutamine echocardiography in patients with an intermediate pretest probability of CAD.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2. Adenosine or dipyridamole stress myocardial perfusion imaging or dobutamine echocardiography in patients with prior revascularization (either PTCA or CABG).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Class IIb",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1. Adenosine or dipyridamole stress myocardial perfusion imaging or dobutamine echocardiography in patients with a low or high probability of CAD in the absence of electronically paced ventricular rhythm or left bundle-branch block.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       2. Adenosine or dipyridamole myocardial perfusion imaging in patients with a low or a high probability of CAD and one of the following baseline ECG abnormalities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Electronically paced ventricular rhythm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. Left bundle-branch block",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       ACC/AHA classification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class I:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       <strong>",
"        Class II:",
"       </strong>",
"       Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIa:",
"       </strong>",
"       Weight of evidence/opinion is in favor of usefulness/efficacy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <strong>",
"        Class IIb:",
"       </strong>",
"       Usefulness/efficacy less well established by evidence/opinion.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Class III:",
"       </strong>",
"       Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful and in some cases may be harmful.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data modified from: Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparative advantages of stress echocardiography and stress radionuclide perfusion imaging in diagnosis of coronary heart disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Advantages of stress echocardiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Higher specificity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Versatility - more extensive evaluation of cardiac anatomy and function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Greater convenience, efficacy, availability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Lower cost",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Advantages of stress perfusion imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Higher technical success rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Higher sensitivity - especially for single vessel coronary disease involving the left circumflex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Better accuracy in evaluating possible ischemia when multiple resting left ventricular wall motion abnormalities are present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. More extensive published data base - especially in evaluation of prognosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149. Copyright &copy; 2003 American College of Cardiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_18_5423=[""].join("\n");
var outline_f5_18_5423=null;
  